Novel 2, 6-dioxaspiro [4, 5] decane derivative as well as preparation method and medical application thereof
Through the development of new 2,6-dioxaspiro[4,5]decane compounds, the existing Gi protein biased μ receptor agonists have not been able to effectively solve the respiratory depression problem and the injection form is not Problems suitable for long-term treatment have achieved selective activation of the Gi signaling pathway and the reduction of the β-arrestin signaling pathway, providing better analgesic effects and safety, and are suitable for oral administration.
Patent Information
- Application Number
- CN202410560985.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-01-08
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-08
AI Technical Summary
Although existing Gi protein biased μ receptor agonists have reduced adverse effects on opioids in clinical practice, they have not effectively solved the problem of respiratory depression, and the injection form is not suitable for long-term treatment and cannot meet oral administration. need.
A new class of 2,6-dioxaspiro[4,5]decane compounds and their pharmaceutically acceptable salts or stereoisomers are developed to activate the Gi signaling pathway of the μ receptor through oral administration, reducing the Activation of β-arrestin signaling pathway, thereby reducing adverse reactions.
Selective activation of the Gi signaling pathway is achieved, adverse reactions related to the β-arrestin signaling pathway are reduced, and better analgesic effects and safer drug properties are provided, which are suitable for long-term oral treatment.
Smart Images

Figure CN118908972A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a series of novel 2,6-dioxaspiro[4,5]decane compounds and their use in preparing drugs for opioid receptor μ receptor agonist-related diseases, and specifically to derivative compounds represented by the general formula, their tautomers or pharmaceutically acceptable compositions thereof. Background Art
[0002] Opioids are currently the most effective analgesics in clinical practice, but they are often prone to cause some target-related side effects, such as respiratory depression and constipation. After binding to the ligand, opioid GPCR receptors can simultaneously affect multiple downstream signaling pathways, including the Gi protein signaling pathway and the β-Arrestin signaling pathway. Current studies have shown that the analgesic effect of opioids comes from the Gi protein signaling pathway of the μ receptor, while related side effects, such as respiratory depression and constipation, are related to the β-Arrestin signaling pathway downstream of the μ receptor. Compared with wild-type mice, the analgesic effect of morphine injected into β-Arrestin-2 knockout mice was enhanced, the duration of efficacy was prolonged, and the related adverse reactions were weakened. Therefore, Gi protein-biased μ receptor agonists can selectively activate the Gi signaling pathway, but have no effect on the β-Arrestin pathway, or have a small effect. Therefore, it can be expected that Gi protein-biased μ receptor agonists have better analgesic effects in clinical practice, while opioid-related adverse reactions are greatly reduced.
[0003] Travena's Gi protein-biased μ receptor agonist TRV-130 (Oliceridine) is currently on the market. TRV130 has achieved selectivity for Gi proteins to a certain extent, but still has a certain activation effect on the β-arrestin2 signaling pathway, and has not achieved complete separation of the Gi pathway and the β-arrestin2 pathway (Dewire SM, et al. Journal of Pharmacology & Experimental Therapeutics, 2013, 344 (3): 708-717.). The Phase III clinical study of TRV130 for postoperative pain achieved the primary endpoint (pain score) and was non-inferior to morphine; but did not achieve the secondary endpoint (indicators related to respiratory depression). Although the indicators related to respiratory depression showed a certain degree of improvement in numerical terms compared with morphine, no statistically significant difference was found. Therefore, the problem of respiratory depression was not solved, and it has the risks of constipation, QTc interval prolongation, and liver damage (related to the accumulation of metabolites in the liver) (Singla NK, et al. Pain Pract. 2019 Sep; 19(7): 715-731.; OLINVYK Multi-Discipline Review. FDA. (https: / / www.accessdata.fda.gov / drugsatfda_docs / nda / 2020 / 210730Orig1s000 MultidisciplineR.pdf.).
[0004] CN111148515B discloses a class of Gi protein-biased μ receptor agonist compounds, which have a significant agonist effect on the μ receptor cAMP signaling pathway, but have almost no agonist effect on the μ receptor β-arrestin signaling pathway, and can effectively reduce adverse reactions associated with the β-arrestin signaling pathway.
[0005] However, the compounds disclosed in TRV-130 and CN111148515B both require injection for administration, which is not suitable for long-term treatment in terms of patient compliance. Therefore, the development of Gi protein "biased" opioid receptor μ receptor agonists that meet the requirements of oral administration has great clinical advantages and huge market demand. Summary of the invention
[0006] In one embodiment of the present invention, a compound represented by formula (I) or (IA), a pharmaceutically acceptable salt or stereoisomer thereof is provided:
[0007]
[0008] in:
[0009] Ring A is
[0010] X 1a Selected from: C(R 1a )2. NR 1a or O;
[0011] X 1b Selected from: C(R 1b )2. NR 1b or O;
[0012] X2 is selected from: CR2 or N;
[0013] X3 is selected from: CR3 or N;
[0014] X4 is selected from: CR4 or N;
[0015] X5 is selected from: CR5 or N;
[0016] X6 is selected from: CH or N;
[0017] Each R 1a and R 1b Each independently selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, the C 1-6 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl C(=O)NH-, C 1-6 AlkylNHC(=O)-, or C 1-6 Alkylamino substituted;
[0018] R1, R2, R3, R4, R5 are each independently selected from: H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl C(=O)-, C 1-6 Haloalkyl C(=O)-, (C 1-6 Alkyl)2N-, (C 1-6 alkyl) 2NC(=O)-, cyano, the C 1-6 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-6 Alkoxy, C1-6 Haloalkoxy, or (C 1-6 alkyl) 2N-substituted;
[0019] R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, or halogen.
[0020] Provided that: the compound of formula (I), its pharmaceutically acceptable salt or stereoisomer does not include:
[0021]
[0022]
[0023] In one embodiment of the present invention, a compound represented by formula (II), a pharmaceutically acceptable salt or a stereoisomer thereof is provided:
[0024]
[0025] in:
[0026] Ring A is
[0027] X 1a Selected from: C(R 1a )2. NR 1a or O;
[0028] X 1b Selected from: C(R 1b )2. NR 1b or O;
[0029] X2 is selected from: CR2 or N;
[0030] X3 is selected from: CR3 or N;
[0031] X4 is selected from: CR4 or N;
[0032] X5 is selected from: CR5 or N;
[0033] X6 is selected from: CH or N;
[0034] Y is selected from a bond or -(C=O)-;
[0035] Each R 1a and R 1b Each independently selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-6 Cycloalkoxy, C1-6 Alkylamino, C 1-6 Alkylthio, the C 1-6 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl C(=O)NH-, C 1-6 AlkylNHC(=O)-, or C 1-6 Alkylamino substituted;
[0036] R1, R2, R3, R4, R5 are each independently selected from: H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 1-6 Alkyl C(=O)-, C 1-6 Haloalkyl C(=O)-, (C 1-6 Alkyl)2N-, (C 1-6 alkyl) 2NC(=O)-, cyano, the C 1-6 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-6 Alkoxy, C 1-6 Haloalkoxy, or (C 1-6 alkyl) 2N-substituted;
[0037] R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, or halogen.
[0038] Provided that: the compound of formula (II), its pharmaceutically acceptable salt or stereoisomer does not include:
[0039]
[0040] In some embodiments of the present invention, a compound represented by formula (IIA), a pharmaceutically acceptable salt or a stereoisomer thereof is provided:
[0041]
[0042] in:
[0043] Ring A is
[0044] X 1a Selected from: C(R 1a )2. NR 1a or O;
[0045] X 1b Selected from: C(R 1b )2. NR 1b or O;
[0046] X2 is selected from: CR2 or N;
[0047] X3 is selected from: CR3 or N;
[0048] X4 is selected from: CR4 or N;
[0049] X5 is selected from: CR5 or N;
[0050] X6 is selected from: CH or N;
[0051] Y is selected from a bond or -(C=O)-;
[0052] Each R 1a and R 1b Each independently selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, the C 1-6 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkyl C(=O)NH-, C 1-6 Alkyl NHC(=O)-, or C 1-6 Alkylamino substituted;
[0053] R1, R2, R3, R4, R5 are each independently selected from: H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkyl C(=O)-, C 1-6 Haloalkyl C(=O)-, (C 1-6 Alkyl)2N-, (C 1-6 alkyl) 2NC(=O)-, cyano, the C 1-6 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-6 Alkoxy, C 1-6 Haloalkoxy, or (C 1-6 alkyl) 2N-substituted;
[0054] R6, R7a , R 7b , R 7c , R 7d Each is independently selected from: H, or halogen.
[0055] Provided that: the compound of formula (IIA), its pharmaceutically acceptable salt or stereoisomer does not include:
[0056]
[0057] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: Ring A is:
[0058] The other groups are as defined herein.
[0059] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: each R 1a Independently selected from: H, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkoxy, C 1-3 Alkylamino, C 1-3 Alkylthio, the C 1-3 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Alkyl C(=O)NH-, C 1-3 AlkylNHC(=O)-, or C 1-3 The other groups are as defined in the present invention.
[0060] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: each R 1b Independently selected from: H, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 3-6 Cycloalkoxy, C 1-3 Alkylamino, C 1-3 Alkylthio, the C 1-3 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Alkyl C(=O)NH-, C 1-3 AlkylNHC(=O)-, or C 1-3 The other groups are as defined in the present invention.
[0061] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: each R 1a independently selected from: H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, pentachloroethoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, methylamino, ethylamino, methylthio, ethylthio, wherein the terminal carbon atom of the methoxy, ethoxy, n-propoxy, isopropoxy is optionally The invention may be substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, CH3C(=O)NH-, CH3CH2C(=O)NH-, CH3NHC(=O)-, CH3CH2NHC(=O)-, methylamino, or ethylamino; and other groups are as defined in the present invention.
[0062] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: each R 1bindependently selected from: H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, pentachloroethoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, methylamino, ethylamino, methylthio, ethylthio, wherein the terminal carbon atom of the methoxy, ethoxy, n-propoxy, isopropoxy is optionally The invention may be substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, CH3C(=O)NH-, CH3CH2C(=O)NH-, CH3NHC(=O)-, CH3CH2NHC(=O)-, methylamino, or ethylamino; and other groups are as defined in the present invention.
[0063] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: R1, R2, R3, R4, and R5 are each independently selected from: H, halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 1-3 Alkyl C(=O)-, C 1-3 Haloalkyl C(=O)-, (C 1-3 Alkyl)2N-, (C 1-3 alkyl) 2NC(=O)-, cyano, the C 1-3 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-3 Alkoxy, C 1-3 Haloalkoxy, or (C 1-3 The other groups are as defined in the present invention.
[0064] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: R1, R2, R3, R4, and R5 are each independently selected from the group consisting of: H, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, fluoromethyl, chloromethyl, difluoromethyl, dichloromethyl, trifluoromethyl, trichloromethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2,2-trifluoroethyl yl, 2,2,2-trichloroethyl, pentafluoroethyl, pentachloroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, pentachloroethoxy, CH3C(=O)-, CH 3CH2C(=O)-, FCH2C(=O)-, ClCH2C(=O)-, F2CHC(=O)-, Cl2CHC(=O)-, CF3C(=O)-, CCl3C(=O)-, C F3CH2C(=O)-, CCl3CH2C(=O)-, (CH3)2N-, (CH3CH2)2N-, (CH3)2NC(=O)-, (CH3CH2)2NC(=O)-, cyanide The methyl, ethyl, n-propyl, isopropyl terminal carbon atom is optionally substituted by methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, (CH3)2N-, or (CH3CH2)2N-; other groups are as defined in the present invention.
[0065] In some embodiments of the present invention, in the compound represented by formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, F, Cl, Br, or I; other groups are as defined in the present invention.
[0066] In some embodiments of the present invention, in the compound represented by formula (I) or (IA), or a pharmaceutically acceptable salt or stereoisomer thereof: Ring A is:
[0067] X2 is selected from: CR2;
[0068] X3 is selected from: CR3;
[0069] X4 is selected from: CR4;
[0070] X5 is selected from: CR5;
[0071] X6 is selected from: CH or N;
[0072] R 1a Selected from: H;
[0073] R 1b Selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy; R 1b Preferred from: H, C 1-3 Alkyl, C 1-3 Alkoxy; R 1b More preferably selected from: H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy;
[0074] R2, R3, R4, R5 are each independently selected from: H, halogen (preferably: F, Cl, Br, I);
[0075] R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, or halogen (preferably selected from: F, Cl, Br, I).
[0076] In some embodiments of the present invention, in the compound represented by formula (II) or (IIA), or a pharmaceutically acceptable salt or stereoisomer thereof: Ring A is:
[0077] X2 is selected from: CR2;
[0078] X3 is selected from: CR3;
[0079] X4 is selected from: CR4;
[0080] X5 is selected from: CR5;
[0081] X6 is selected from: CH or N;
[0082] Y is selected from a bond;
[0083] R 1a Selected from: H;
[0084] R 1b Selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy; R 1b Preferred from: H, C1-3 Alkyl, C 1-3 Alkoxy; R 1b More preferably selected from: H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy;
[0085] R2, R3, R4, R5 are each independently selected from: H, halogen (preferably: F, Cl, Br, I);
[0086] R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, or halogen (preferably selected from: F, Cl, Br, I).
[0087] In some embodiments of the present invention, the following compounds, pharmaceutically acceptable salts or stereoisomers thereof are provided:
[0088]
[0089]
[0090]
[0091]
[0092] In some embodiments of the present invention, the following compounds, pharmaceutically acceptable salts or stereoisomers thereof are provided:
[0093]
[0094]
[0095]
[0096]
[0097] The present invention also provides a pharmaceutical composition, comprising any one of the above compounds or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition can be prepared into various pharmaceutically acceptable dosage forms, such as tablets, capsules, oral liquids, granules, injections or various sustained-release preparations. The pharmaceutical composition can be administered orally or parenterally (such as intravenously, subcutaneously or topically). The dosage can be appropriately adjusted according to the patient's age, gender and disease type, and the general daily dose is about 1-200 mg.
[0098] The present invention also provides methods / uses of the compound, its pharmaceutically acceptable salt, its stereoisomer, or its pharmaceutical composition as a drug. The compound, its pharmaceutically acceptable salt, its stereoisomer, or its pharmaceutical composition can prevent, treat or improve the pathology and / or symptoms of diseases in animals and humans, and has good physicochemical properties and oral bioavailability.
[0099] The present invention further provides the use of the above-mentioned compound, its pharmaceutically acceptable salt, stereoisomer, or pharmaceutical composition in the preparation of medicine. The compound, its pharmaceutically acceptable salt, stereoisomer, or medicine is used for the prevention and / or treatment of MOR receptor agonist (opioid receptor μ receptor) mediated related diseases in medicine, and has good physicochemical properties and oral bioavailability. The MOR receptor agonist mediated related diseases include pain, inflammation, immune dysfunction, esophageal reflux, neurological and psychiatric disorders, respiratory diseases, digestive system diseases, tumor system diseases, muscle and skeletal system diseases, ENT diseases, skin diseases, blood and lymphatic system diseases, endocrine system diseases, vascular diseases, urinary and reproductive diseases, drug and alcohol abuse, gastritis or diarrhea, pruritus, anesthesia, sedation, infection. The pain includes neuropathic pain, nociceptive pain, mixed pain, mixed pain inflammatory pain, visceral pain, migraine and cancer-related pain.
[0100] Definition and Description
[0101] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.
[0102] The term "pharmaceutically acceptable" as used herein refers to compounds, compositions and / or dosage forms that are, within the scope of reliable medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, and are commensurate with a reasonable benefit / risk ratio.
[0103] The "pharmaceutically acceptable salts" mentioned in the present invention refer to salts of the compounds of the present invention, which are prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids and bases. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, organic acid salts; they also include salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic functional groups and can be converted into any acid addition salt.
[0104] Certain compounds of the present invention may possess asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are all within the scope of the present invention.
[0105] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present invention.
[0106] Unless otherwise indicated, the term "enantiomer" or "optical isomer" refers to stereoisomers that are mirror images of one another.
[0107] Unless otherwise indicated, the term "cis-trans isomers" or "geometric isomers" arises from the inability of a ring to rotate freely about double bonds or single bonds of ring carbon atoms.
[0108] Unless otherwise indicated, the term "diastereomer" refers to stereoisomers that have two or more chiral centers and that are not mirror images of each other.
[0109] Unless otherwise indicated, "(D)" or "(+)" indicates dextrorotatory, "(L)" or "(-)" indicates levorotatory, and "(DL)" or "(±)" indicates racemic.
[0110] Unless otherwise specified, the key is a solid wedge. and dotted wedge key To indicate the absolute configuration of a stereocenter, use a straight solid bond. and straight dashed key To indicate the relative configuration of a stereocenter, use a wavy line Indicates a wedge-shaped solid key or dotted wedge key Or use a wavy line Represents a straight solid bond and straight dashed key
[0111] The pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. In general, the preparation method of the salt is: in water or an organic solvent or a mixture of the two, through the reaction of these compounds in free acid or base form with a stoichiometric amount of an appropriate base or acid to prepare.
[0112] The term "pharmaceutically acceptable carrier" refers to any preparation or carrier medium representative of a carrier that can deliver an effective amount of the active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects on the host or patient, including but not limited to: binders, fillers, lubricants, disintegrants, wetting agents, dispersants, solubilizers, suspending agents, etc.
[0113] The present invention is intended to include all isotopes of atoms present in the compounds of the present invention. Isotopes include those atoms having the same atomic number but different mass numbers. As a general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and 14 C. Isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically labeled reagent in place of the non-labeled reagent otherwise employed.
[0114] Unless otherwise specified, "alkyl" is used to refer to a straight or branched saturated hydrocarbon group, which may be monosubstituted (such as -CH2F) or polysubstituted (such as -CF3), and may be monovalent (such as methyl), divalent (such as methylene) or polyvalent (such as methine). For example, C1-C6 means 1 to 6 carbon atoms, C 1-6 Selected from C1, C2, C3, C4, C5, C6; examples of alkyl include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, s-butyl, t-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl, 1-ethylpropyl), hexyl (e.g., n-hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl) and the like.
[0115]
[0043] Unless otherwise stated, "halo" or "halogen," by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom.
[0116] "Haloalkyl" is used to refer to a monohalogenated / polyhalogenated straight or branched chain alkyl group. Typical haloalkyl groups include C 1-6Haloalkyl, for example: C1, C2, C3, C4, C5, C6 haloalkyl. For example, examples of C1-C6 haloalkyl include, but are not limited to: fluoromethyl, chloromethyl, difluoromethyl, dichloromethyl, trifluoromethyl, trichloromethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, and pentachloroethyl.
[0117] Unless otherwise specified, "alkoxy" is used to represent an alkyl group (including cycloalkyl or haloalkyl) having a specific number of carbon atoms attached through an oxygen bridge. Typical alkoxy groups include C 1-6 Alkoxy, for example: C1, C2, C3, C4, C5, C6 alkoxy, C3, C4, C5, C6 cycloalkoxy, C1, C2, C3, C4, C5, C6 halogenated alkoxy. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, S-pentoxy, hexoxy, 2-ethylbutoxy. Examples of cycloalkoxy include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Examples of halogenated alkoxy include, but are not limited to, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, pentachloroethoxy.
[0118] Unless otherwise specified, "cycloalkyl" includes any stable cyclic or polycyclic hydrocarbon radical, any carbon atom of which is saturated, which may be mono- or poly-substituted, and which may be mono-, di- or polyvalent. 3-6 Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
[0119] Unless otherwise specified, "alkylamino" is used to refer to a saturated aliphatic hydrocarbon group containing 1 to 6 carbon atoms in the molecule with an -NH- or -N- group inserted in any reasonable position, including monoalkylamino, dialkylamino and cycloalkylamino. Typical alkylamino groups include C 1-6 Alkylamino, for example: C1, C2, C3, C4, C5, C6 alkylamino, typical examples include but are not limited to methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, diethylamino, di-n-propylamino, diisopropylamino and the like.
[0120] Unless otherwise specified, the term "alkylthio" is used to refer to a saturated aliphatic hydrocarbon group containing 1 to 6 carbon atoms with a sulfur atom inserted at any reasonable position in the molecule. Typical alkylthio groups include C 1-6Alkylthio, for example: C1, C2, C3, C4, C5, C6 alkylthio, typical examples include but are not limited to methylthio, ethylthio, n-propylthio, isopropylthio and the like.
[0121] Unless otherwise specified, the term "bond / single bond" refers to a chemical bond between atoms used to connect or interact with each other, such as an ionic bond, a covalent bond, a coordination bond, etc.; in the molecular structure of an organic compound, a "bond / single bond" is usually a covalent bond. When one or more variables between two atoms / groups are defined as a "bond / single bond", it usually means that the two atoms / groups are directly connected by a "bond / single bond".
[0122] Compounds are manually or The software names were used, and commercially available compounds were named using the supplier's catalog names. DETAILED DESCRIPTION
[0123] The present invention is further described below in conjunction with specific embodiments and test examples, but the scope of the present invention is not limited in any form.
[0124] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS).
[0125] NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using an AVANCE III 600 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD) and deuterated chloroform (CDCl3) as the solvents, and tetramethylsilane (TMS) as the internal standard.
[0126] Liquid chromatography-mass spectrometry (LC-MS) was performed using a Shimadzu LCMS2020 mass spectrometer, and HPLC was performed using a Shimadzu LC20A liquid chromatograph.
[0127] The thin layer chromatography silica gel plate used was Yantai Jiangyou silica gel plate, the specification used for TLC was 0.2mm±0.03mm, and the specification used for thin layer chromatography separation and purification products was 0.4mm-0.5mm.
[0128] The following abbreviations correspond to the reagent names:
[0129] abbreviation Reagent name DCM Dichloromethane EA Ethyl acetate PE Petroleum ether <![CDATA[Boc2O]]> Di-tert-butyl dicarbonate TEMPO 2,2,6,6-Tetramethylpiperidinyloxide IBCF Isobutyl chloroformate TFA Trifluoroacetic acid EDCI 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride DIEA N,N-Diisopropylethylamine ACN Acetonitrile
[0130] Example 1: Synthesis of Compound 1
[0131] Synthesis route:
[0132]
[0133] Step 1: Synthesis of compound 1-2
[0134] The raw material 1-1 (2.0g, 6.77mmol) was dissolved in the solvent DCM (20mL), and oxalyl chloride (2.58g, 20.3mmol) was added dropwise at room temperature. After the addition, 2 drops of dry DMF were added to catalyze the reaction. The reaction was continued at room temperature for 2 hours. The reaction solution was directly concentrated to dryness, and the residue was dissolved in DCM (20mL). Under an ice bath, the above solution was slowly added dropwise to a dichloromethane (20ml) solution of N,O-dimethylhydroxylamine hydrochloride (0.99g, 10.2mmol) and triethylamine (2.06g, 20.3mmol). Water (50mL) was added to quench the reaction, and DCM (100mL×3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and purified by column chromatography (DCM:CH3OH=10:1) to obtain compound 1-2 (1.8g, yield 78.5%). LCMS=339.0[M+1] +
[0135] Step 2: Synthesis of Compound 1-3
[0136] Compound 1-2 (1.0 g, 2.96 mmol) was dissolved in dry THF (10 mL), and lithium aluminum hydride (110 mg, 2.95 mmol) was added in batches under nitrogen protection in an ice-water bath. The reaction was allowed to react at room temperature for 3 h. The reaction solution was poured into ice water (50 mL) to quench the reaction, and extracted with ethyl acetate (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (DCM: CH3OH = 10: 1) to obtain compound 1-3 (0.6 g, yield 72.3%). LCMS = 280.1 [M+1] +
[0137] Step 3: Synthesis of Compound 1
[0138] Compound 1-3 (0.25 g, 0.895 mmol) and chloro-1,2,3,4-tetrahydronaphthalene-1-amine (0.29 g, 1.34 mmol) were dissolved in tetrahydrofuran (10 mL), two drops of acetic acid were added, and the mixture was stirred at room temperature for 30 min. Sodium triacetyl borohydride (0.38 g, 1.79 mmol) was added in batches. The mixture was reacted at room temperature for 3 hours. Water (20 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude oil. Column chromatography purification (DCM: CH3OH = 10: 1) gave compound 1 (0.23 g, yield 57.8%, yellow oil). LCMS = 445.0 [M+1] + . 1H NMR (400MHz, DMSO) δ8.53 (d, J=2.9Hz, 1H), 7.67 (td, J=8.8, 2.9Hz, 1H), 7.57 (dd, J=8.3,3.8Hz,1H),7.24(d,J=7.7Hz,1H),7.12(dq,J=13.4,7.5Hz,2H),3.68-3.6 4(m,3H),3.59-3.40(m,4H),2.70-2.52(m,2H),2.44-2.25(m,3H),2.07-1.92(m, 1H),1.87-1.77(m,3H),1.68-1.49(m,5H),1.33-1.20(m,2H),1.12-1.01(m,1H).
[0139] Example 2: Synthesis of Compound 2
[0140] Synthesis route:
[0141]
[0142] Step 1: Synthesis of compound 2-1
[0143] Mg (0.385 g, 15.4 mmol) and I2 (0.18 g, 0.702 mmol) were dissolved in tetrahydrofuran (15 mL), 4-bromobutylbenzyl ether (3.75 g, 15.4 mmol) was added under nitrogen protection, and the mixture was stirred at 40°C for 40 min. The mixture was cooled to 0°C, and compound 1-2 (0.95 g, 2.81 mmol) was added, and the mixture was reacted at room temperature for 1 h. Saturated ammonium chloride (100 mL) was added to quench the reaction, and ethyl acetate (50 mL × 3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (EA: PE = 10-50%) to obtain compound 2-1 (0.95 g, yield 79.1%, oily substance). LCMS: 442.3 [M+1] + .
[0144] Step 2: Synthesis of compound 2-2
[0145] Dissolve compound 2-1 (0.95 g, 2.15 mmol) in methanol (25 mL), add ammonium acetate (3.32 g, 43.0 mmol) and NaBH3CN (2.03 g, 32.3 mmol), and protect with nitrogen. React at 70 °C for 15 h. Add water (50 mL) to quench the reaction, add ethyl acetate (50 mL × 3) to extract, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate, and the residue is chromatographed on a silica gel column (EA: PE = 10-50%) to obtain compound 2-2 (0.94 g, yield: 98.9%). LCMS: 443.2 [M+1] +
[0146] Step 3: Synthesis of compound 2-3
[0147] Compound 2-2 (0.94 g, 2.12 mmol) was dissolved in methanol (15 mL), and Boc2O (0.93 g, 4.25 mmol) and DIEA (0.82 g, 6.37 mmol) were added, and the mixture was reacted at room temperature for 1 h. Water (50 mL) was added to quench the reaction, and ethyl acetate (50 mL × 3) was added to extract. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (EA: PE = 10-40%) to obtain compound 2-3 (1.12 g, yield: 97.4%, oil). LCMS: 543.3 [M+1] + .
[0148] Step 4: Synthesis of compound 2-4
[0149] Dissolve compound 2-3 (1.1 g, 2.03 mmol) in methanol (15 mL), add Pd / C (0.4 g, 0.376 mmol, 10%) and Pd(OH)2 (0.4 g, 0.285 mmol), and protect with nitrogen. Replace with hydrogen three times, pass hydrogen (15 psi), and react at room temperature for 5 h. Filter and concentrate the filtrate to obtain compound 2-4 (0.9 g, crude product). LCMS: 453.4 [M+1] + .
[0150] Step 5: Synthesis of Compound 2-5
[0151] Compound 2-4 (0.82 g, 1.81 mmol) was dissolved in acetonitrile (15 mL) and water (15 mL), and NaH2PO4 (0.22 g, 1.81 mmol), Na2HPO4 (0.26 g, 1.81 mmol), TEMPO (0.056 g, 0.36 mmol) and NaClO (0.40 mg, 5.44 mmol) were added. The mixture was stirred for 10 min under nitrogen protection, and NaClO2 (0.49 g, 5.44 mmol) was added. The reaction was allowed to react at room temperature for 30 min. Water (100 mL) was added to quench the reaction, and the pH was adjusted to 5 with dilute hydrochloric acid. Ethyl acetate (100 mL×3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (methanol:DCM=0-20%) to obtain compound 2-5 (0.59 g, yield: 70.2%, oily substance). LCMS: 467.3[M+1] + .
[0152] Step 6: Synthesis of Compound 2-6
[0153] Compound 2-5 (0.59 g, 1.26 mmol) was dissolved in tetrahydrofuran (10 mL), and IBCF (0.26 g, 1.9 mmol) and DIEA (1.6 g, 12.6 mmol) were added, and the mixture was reacted at 0°C for 0.5 h. Dimethylhydroxylamine hydrochloride (0.62 g, 6.32 mmol) was added, and the mixture was reacted at room temperature for 1 h. Water (50 mL) was added to quench the reaction, and ethyl acetate (50 mL × 3) was added to extract the mixture. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (methanol: DCM = 0-10%) to obtain compound 2-6 (0.58 g, yield: 90.6%, oil). LCMS: 510.3 [M+1] + .
[0154] Step 7: Synthesis of Compound 2-7
[0155] Mg (328 mg, 13.7 mmol) and I2 (144 mg, 0.569 mmol) were dissolved in tetrahydrofuran (15 mL), and m-chlorobromobenzene (2180 mg, 11.4 mmol) was added under nitrogen protection, and stirred at 40°C for 3 h. The temperature was lowered to 0°C, and compound 2-6 (585 mg, 1.15 mmol) was added, and the reaction was allowed to react at room temperature for 1 h. Saturated ammonium chloride (50 mL) was added to quench the reaction, and ethyl acetate (50 mL×3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (EA:PE=10-50%) to obtain compound 2-7 (320 mg, yield 50.0%, oil). LCMS: 561.3[M+1] + .
[0156] Step 8: Synthesis of Compound 2
[0157] Compound 2-7 (0.32 g, 0.570 mmol) was dissolved in DCM (25 mL), and TFA (2.5 mL) was added at 0°C under nitrogen protection. The reaction was allowed to react at room temperature for 1 h. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in methanol (10 mL). NaBH3CN (0.036 g, 0.573 mmol) was added and the reaction was allowed to react at room temperature for 1 h. Water (50 mL) was added to quench the reaction, and ethyl acetate (50 mL×3) was added to extract. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (methanol: DCM = 0-20%) to obtain compound 2 (0.10 g, yield: 40.0%, white solid). LCMS: 445.3 [M+1] + . 1H NMR (400MHz, CDCl3) δ8.50-8.29(m,1H),7.49-7.33(m,2H),7.26-7.20(m,1H),7.18(br d,J=4.4Hz,1H),7.16-6.94(m,2H),3.92-3.67(m,5H),3.59-3.51(m,1H),3.47-3.26(m,1H),2.62-2.33 (m,3H),2.02-1.89(m,2H),1.85-1.77(m,2H),1.69-1.62(m,2H),1.11-1.03(m,2H),0.95-0.82(m,5H).
[0158] Example 3: Synthesis of Compound 3
[0159] Synthesis route:
[0160]
[0161] Step 1: Synthesis of compound 3-2
[0162] The raw material 3-1 (25 g, 90.5 mmol) was dissolved in NH3 / MeOH (300 mL, 7N), and Raney nickel (10.8 g, 63.3 mmol, 50%) was added at 0°C under nitrogen protection. Hydrogen was introduced and replaced three times, and the reaction was carried out at room temperature for 48 hours. The reaction was filtered and the filtrate was concentrated to obtain compound 3-2 (25.3 g, crude product). LCMS: 281.3 [M+1] + .
[0163] Step 2: Synthesis of compound 3-3
[0164] Compound 3-2 (25 g, 89.2 mmol) was dissolved in methanol (300 mL), and Boc2O (20.4 g, 93.6 mmol) was added. The reaction was allowed to react at room temperature for 2 h. Water (150 mL) was added to quench the reaction, and ethyl acetate (150 mL×3) was added to extract. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by prep-SFC (DAICEL CHIRALPAK AD (250 mm*50 mm, 10 um), CO2-EtOH (0.1% NH3H2O), 25% B) to obtain compound 3-3 (6 g, yield: 17.8%, waxy body). LCMS: 381.3 [M+1] + .
[0165] Step 3: Synthesis of compound 3-4
[0166] Dissolve compound 3-3 (1 g, 2.63 mmol) in dioxane (3 mL), add HCl / dioxane (4 M, 10 mL), and react at room temperature for 2 h. The reaction solution was concentrated under reduced pressure to obtain compound 3-4 (0.83 g, crude product). LCMS: 281.3 [M+1] + .
[0167] Step 4: Synthesis of Compound 3-6
[0168] The raw material 3-5 (5.0 g, 37.0 mmol) and DIEA (14 g, 111 mmol) were dissolved in DCM (100 mL), and acetyl chloride (3.2 g, 40.7 mmol) was added at 0°C. The reaction was allowed to react at room temperature for 2 h. Saturated sodium bicarbonate (100 mL) was added to quench the reaction, and ethyl acetate (100 mL×3) was added to extract. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was subjected to silica gel column chromatography (EA:PE=0-10%) to obtain compound 3-6 (4.8 g, yield: 73.2%, oil). LCMS: 178.2[M+1] + .
[0169] Step 5: Synthesis of Compound 3-7
[0170] Dissolve compound 3-6 (5 g, 28.2 mmol) in acetonitrile (120 mL), add silver fluoride (28.8 g, 198 mmol) under nitrogen protection. React at 70°C for 1 h. Cool to room temperature, add potassium carbonate solution (5%), adjust pH to 9, and filter. Extract the filtrate with ethyl acetate (100 mL×3). Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate. The residue is chromatographed on a silica gel column (EA:PE=0-30%) to obtain compound 3-7 (3.8 g, yield: 69.1%, oily substance). LCMS: 136.2[M-AcO] + .
[0171] Step 6: Synthesis of Compound 3-8
[0172] Compound 3-7 (1.5 g, 7.68 mmol) was dissolved in tetrahydrofuran (10 mL) and water (10 mL), and LiOH was added at 0°C. . H2O (0.64 g, 15.4 mmol). React at room temperature for 1 h. Add dilute hydrochloric acid (1N) to adjust pH = 7, add ethyl acetate (50 mL × 3) for extraction. Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain compound 3-8 (1 g, crude product). LCMS: 136.2 [M-OH] + .
[0173] Step 7: Synthesis of Compound 3-9
[0174] Dissolve compound 3-8 (1.7 g, 11.1 mmol) in DCM (30 mL) and add Dess-Martin periodinane (5.6 g, 13.3 mmol). React at room temperature for 1 h. Add saturated sodium bicarbonate (50 mL) and extract with ethyl acetate (50 mL×3). Combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate, and the residue is chromatographed on a silica gel column (EA:PE=0-30%) to obtain compound 3-9 (1 g, yield 58.6%). LCMS: 152.1[M+1] + .
[0175] Step 8: Synthesis of compound 3
[0176] Dissolve compound 3-4 (0.80 g, 2.53 mmol) in methanol (40 mL), add sodium acetate (1.0 g, 12.6 mmol) and compound 3-9 (0.50 g, 3.28 mmol), stir at room temperature for 30 min. Add sodium triacetylborohydride (0.79 g, 12.6 mmol) in batches, and react at room temperature for 12 hours. Water (20 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue (i.e., compound 3) was purified by prep-HPLC (Phenomenex Luna C18 150*25mm*10um; mobile phase: [water(TFA)-ACN]; gradient: 12%-42% B over 9min) and prep-SFC (chromatographic column: DAICEL CHIRALCEL OD (250mm*30mm, 10um); mobile phase: [CO2-MeOH (0.1% NH3H2O)]; B%: 10% methanol, isocratic elution mode) to obtain compound 3-P1 (0.20 g, yield 19.0%, brown solid), retention time: 2.97 min. LCMS=416.0[M+1] + . 1H NMR(CDCl3,400MHz)δ8.44(d,J=2.8Hz,1H),7.56(t,J=7.8Hz,1H),7.39-7.34(m,2H),6.72(d, J=8.0Hz,1H),3.99(t,J=7.2Hz,1H),3.86-3.69(m,5H),3.57(d,J=9.2Hz,1H),2.93-2.86(m,1H ),2.79-2.71(m,1H),2.64(td,J1=11.2Hz,J2=5.2Hz,1H),2.45-2.30(m,3H),2.20(td,J1=11.2 Hz,J2=5.2Hz,1H),2.02-1.91(m,2H),1.81-1.72(m,3H),1.47-1.42(m,1H),1.22-1.14(m,1H).
[0177] Compound 3-P2 (0.20 g, yield 19.0%, brown solid) was obtained, retention time: 4.78 min. LCMS 416.0 [M+1] + . 1 H NMR(CDCl3,400MHz)δ8.46(d,J=2.8Hz,1H),7.58(t,J=8.0Hz,1H),7.41-7.35(m,2H), 6.74(d,J=8.4Hz,1H),3.98(t,J=7.0Hz,1H),3.86-3.71(m,5H),3.56(d,J=9.6Hz,1H) ,2.97-2.90(m,1H),2.80-2.72(m,1H),2.63-2.57(m,1H),2.47-2.32(m,3H),2.29-2. 23(m,1H),2.02-1.91(m,2H),1.86-1.75(m,3H),1.45-1.40(m,1H),1.17-1.09(m,1H).
[0178] Referring to the synthesis method of Example 3 (Compound 3), Compound 4 was synthesized:
[0179]
[0180]
[0181] Example 4: Synthesis of Compound 5 Hydrochloride
[0182] Synthesis route:
[0183]
[0184] Compound 1-3 (222 mg, 0.795 mmol) and (7S)-6,7-dihydro-5H-7-amino-cyclopenta[B]pyridine (189 mg, 1.11 mmol) were dissolved in methanol (10 mL), acetic acid (47.7 mg, 0.794 mmol) was added, and the mixture was stirred at room temperature for 30 min. NaBH3CN (149 mg, 2.38 mmol) was added in batches. The mixture was reacted at room temperature for 12 hours. Water (20 mL) was added to quench the mixture, and ethyl acetate was extracted (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude oil. The residue was purified by prep-HPLC (chromatographic column: Xtimate C18 150*40mm*10um; mobile phase: [water(HCl)-ACN]; gradient: 0%-34% Bover 36 min) to obtain compound 5 hydrochloride (100 mg, yield 29.0%, yellow oil). LCMS=398.2[M+1] + . 1 H NMR(400MHz,MeOD)δ1.33(dt,J=12.98,9.27Hz,1H)1.54(dt,J=12.76,4.38Hz,1H)1.98(ddd,J=14.07,9.76, 4.06Hz,1H)2.10-2.26(m,2H)2.28-2.48(m,2H)2.49-2.59(m,2H)2.65-2.76(m,1H)2.86(td,J=12.10,4.57Hz ,1H)3.11-3.33(m,4H)3.36-3.49(m,1H)3.59(d,J=9.38Hz,1H)3.70-3.94(m,5H)5.03-5.06(m,1H)7.94(dd, J=7.88, 5.63Hz, 1H) 8.03 (dd, J= 9.07, 4.44Hz, 1H) 8.11-8.20 (m, 1H) 8.44 (d, J= 7.88Hz, 1H) 8.73-8.82 (m, 2H).
[0185] Referring to the synthesis method of Example 4 (Compound 5 hydrochloride), the hydrochlorides of Compounds 11 and 13-14 were synthesized:
[0186]
[0187]
[0188] The hydrochlorides of compounds 5, 11, 13-14 are alkalized with aqueous potassium carbonate solution, extracted with ethyl acetate, and the organic phase is concentrated in vacuo to obtain the free bases of compounds 5, 11, 13-14, respectively.
[0189] Example 5: Synthesis of Compound 8
[0190] Synthesis route:
[0191]
[0192]
[0193] Step 1: Synthesis of compound 8-2
[0194] Dissolve the raw material 8-1 (15 g, 96.0 mmol) in toluene (500 mL), add methyl cyanoacetate (14.3 g, 144 mmol), ammonium acetate (2.2 g, 28.8 mmol) and acetic acid (1.2 g, 19.2 mmol). React at 110 ° C for 12 h. Add water (500 mL) at 0 ° C to quench the reaction, add ethyl acetate (500 mL × 3) to extract, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate, and purify the residue by silica gel column chromatography (EA: PE = 0 ~ 30%) to obtain compound 8-2 (22.4 g, yield: 98.2%, oil). LCMS: 238.1 [M + 1] + .
[0195] Step 2: Synthesis of compound 8-3
[0196] Dissolve 4-fluorophenylmagnesium bromide (2M, 78.2mL) in tetrahydrofuran (245mL), add CuI (1.2g, 6.43mmol), and protect with nitrogen. Add a solution of compound 8-2 (15g, 63.2mmol) in tetrahydrofuran (140mL) dropwise at 0℃ and under nitrogen protection. React at room temperature and under nitrogen protection for 3h. Add saturated ammonium chloride (400mL) at 0℃ to quench the reaction, add ethyl acetate (500mL×3) to extract, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate, and purify the residue by silica gel column chromatography (methanol:DCM=0~20%) to obtain compound 8-3 (16g, yield: 75.8%, oily substance). LCMS: 334.2[M+1] + .
[0197] Step 3: Synthesis of compound 8-4
[0198] Compound 8-3 (16 g, 48.0 mmol) was dissolved in ethylene glycol (170 mL), and potassium hydroxide (4.1 g, 72.5 mmol) was added. The reaction was carried out at 120°C for 3 h. The temperature was lowered to room temperature, and water (150 mL) was added to quench the reaction. Ethyl acetate (500 mL×3) was added to extract, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (EA:PE=0-50%) to obtain compound 8-4 (12.7 g, yield: 96.1%, oil). LCMS: 276.1[M+1] + .
[0199] Step 4: Synthesis of compound 8-5
[0200] Compound 8-4 (12.7 g, 46.1 mmol) was dissolved in ethylene glycol (170 mL), and potassium hydroxide aqueous solution (5 M, 203 mL) was added. The reaction was carried out at 110 ° C for 36 h. The temperature was cooled to room temperature, and water (150 mL) was added to quench the reaction. The pH was adjusted to 3 with hydrochloric acid at 0 ° C, and ethyl acetate (500 mL × 3) was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (methanol: DCM = 0-20%) to obtain compound 8-5 (11.3 g, yield: 82.9%, oil). LCMS: 295.2 [M+1] + .
[0201] Step 5: Synthesis of compound 8-6
[0202] Compound 8-5 (4.0 g, 13.6 mmol) and dimethylhydroxylamine hydrochloride (1.6 g, 16.5 mmol) were dissolved in DCM (80 mL), EDCI (3.2 g, 16.8 mmol) and DMAP (0.17 g, 1.37 mmol) were added at 0°C, and stirred at 0°C for 10 min. DIEA (5.3 g, 40.9 mmol) was added at 0°C. The mixture was reacted at room temperature for 12 h. Water (100 mL) was added to quench the reaction, and ethyl acetate (100 mL×3) was added to extract. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (EA:PE=0-50%) to obtain compound 8-6 (4.3 g, yield: 93.6%, oil). LCMS: 338.3[M+1] + .
[0203] Step 6: Synthesis of compound 8-7
[0204] Dissolve compound 8-6 (3 g, 8.89 mmol) in tetrahydrofuran (40 mL), and add lithium aluminum hydride tetrahydrofuran solution (2.5 M, 3.56 mL) dropwise at 0°C under nitrogen protection. React at room temperature for 2 h. Add water (0.34 mL), 15% sodium hydroxide (0.34 mL) and water (1.02 mL) in sequence at 0°C, filter, and wash the filter cake with ethyl acetate. Collect the organic phase, dry over anhydrous sodium sulfate, filter, and concentrate to obtain compound 8-7 (2.5 g, crude product). LCMS: 279.1 [M+1] + .
[0205] Step 7: Synthesis of compound 8
[0206] Dissolve compound 8-7 (2.5 g, 8.98 mmol) and (S)-(+)-1-aminoindene (1.4 g, 10.6 mmol) in methanol (80 mL), add acetic acid (2.3 g, 38.4 mmol), stir at room temperature for 30 min, add NaBH3CN (2.8 g, 44.4 mmol) in batches, and react at room temperature for 12 hours. Water (20 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude oil. The residue (i.e., compound 8) was purified by rapid preparative liquid phase (water (0.1% NH3.H2O)-ACN, ACN: 60%-76%) and prep-SFC (chromatographic column: Phenomenex-Cellulose-2 (250mm*30mm, 10um); mobile phase: [CO2-ACN / MeOH (0.1% NH3H2O)]; B%: 35% methanol, isocratic elution mode) to obtain compound 8-P1 (0.16 g, yield 4.1%, yellow waxy solid), retention time: 4.51 min. LCMS: 430.2 [M+1] + . 1 H NMR (400MHz, DMSO-d6) δ7.41-7.35(m,2H),7.21(s,1H),7.16-7.08(m,4H),3.88(t,J=6.8Hz,1H),3.76-3.68(m,1H),3.67-3.56(m,3H), 3.08(d,J=9.6Hz,1H),2.88-2.75(m,2H),2.69-2.58(m,1H),2.34-2.23(m,1H),2.22-1.93(m,6H),1.84-1.61(m,5H),1.58-1.47(m,1H).
[0207] Compound 8-P2 (0.20 g, yield 5.2%, yellow waxy solid) was obtained, retention time: 5.51 min. LCMS: 430.1 [M+1] + . 1 H NMR(400MHz,DMSO-d6)δ7.41(dd,J=5.6,8.8Hz,2H),7.21(s,1H),7.17-7.10(m,4H),3 .86(t,J=6.8Hz,1H),3.78-3.68(m,2H),3.66-3.48(m,3H),3.43(d,J=9.2Hz,1H),2.8 8-2.73(m,1H),2.70-2.57(m,1H),2.39-2.27(m,1H),2.24-2.05(m,3H),2.03-1.93(m ,1H),1.88(d,J=14.0Hz,1H),1.80-1.47(m,5H),1.45-1.36(m,1H),1.29-1.16(m,1H).
[0208] Compound 8-P3 (0.26 g, yield 6.7%, yellow waxy solid) was obtained, retention time: 6.72 min. LCMS: 430.1 [M+1] + . 1 H NMR(400MHz,DMSO-d6)δ7.41(dd,J=5.6,8.8Hz,2H),7.21(s,1H),7.18-7.06(m,4H),3.88( t,J=6.8Hz,1H),3.78-3.68(m,2H),3.66-3.51(m,3H),3.42(d,J=9.2Hz,1H),2.87-2.75(m ,1H),2.70-2.56(m,1H),2.36-2.23(m,1H),2.22-2.08(m,3H),2.08-1.98(m,1H),1.88(d, J=13.6Hz,1H),1.80-1.56(m,4H),1.56-1.47(m,1H),1.47-1.38(m,1H),1.32-1.17(m,1H).
[0209] Compound 8-P4 (0.21 g, yield 5.4%, yellow waxy solid) was obtained, retention time: 2.89 min. LCMS: 430.1 [M+1] + . 1H NMR (400MHz, DMSO-d6) δ7.39 (dd, J=5.6, 8.8Hz, 2H), 7.23 (s, 1H), 7.19-7.10 (m ,4H),4.00-3.85(m,1H),3.76-3.68(m,1H),3.67-3.57(m,3H),3.07(d,J=9.6Hz ,1H),2.89-2.76(m,2H),2.71-2.59(m,1H),2.43-2.31(m,1H),2.24-2.09(m,3 H),2.05-1.92(m,3H),1.86-1.75(m,2H),1.73-1.64(m,2H),1.64-1.53(m,1H).
[0210] Referring to the synthesis method of Example 5 (Compound 8), Compounds 9 to 10 were synthesized:
[0211]
[0212]
[0213]
[0214] Example 6: Synthesis of Compound 19
[0215] Synthesis route:
[0216]
[0217]
[0218] Step 1: Synthesis of compound 19-2
[0219] Dissolve the raw material 19-1 (10 g, 47.4 mmol) in ethanol (150 mL) and add silver oxide (32.9 g, 142 mmol). React at room temperature for 1 h. Filter, concentrate the filtrate, and purify the residue by silica gel column chromatography (EA:PE = 0-30%) to obtain compound 19-2 (5 g, yield: 59.9%, oil). LCMS: 177.1 [M+1] + .
[0220] Step 2: Synthesis of compound 19
[0221] Compound 3-4 (1.2 g, 3.79 mmol) and compound 19-2 (1.34 g, 7.58 mmol) were dissolved in methanol (60 mL), acetic acid (0.98 g, 16.4 mmol) was added, stirred at room temperature for 30 min, NaBH3CN (1.2 g, 19.1 mmol) was added in batches, and the mixture was reacted at room temperature for 12 hours. Water (20 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude oil. The residue (i.e., compound 19) was purified by rapid preparative liquid chromatography (water (0.1% NH3H2O)-ACN, ACN: 40%-53%) and prep-SFC (chromatographic column: DAICEL CHIRALCEL OX (250mm*30mm, 10um); mobile phase: [CO2-MeOH (0.1% NH3H2O)]; B%: 35% methanol, isocratic elution mode) to obtain compound 19-P1 (291 mg, yield 17.4%), retention time: 5.68 min. LCMS: 441.2 [M+1] + . 1 H NMR(CDCl3,400MHz)δ8.47-8.41(m,1H),7.41-7.34(m,2H),7.34-7.29(m,1H),7.26-7.23(m,1H),7.22-7 .13(m,2H),4.70(t,J=6.0Hz,1H),3.91(t,J=6.0Hz,1H),3.88-3.80(m,2.5H),3.80-3.68(m,3H),3.67-3 .58(m,2H),3.55(d,J=9.2Hz,1H),2.59-2.49(m,2H),2.48-2.37(m,2H),2.23-2.14(m,1H),1.98-1.88(m ,2H),1.83-1.77(m,1H),1.76-1.68(m,2H),1.46-1.39(m,1H),1.24(t,J=7.2Hz,3H),1.19-1.10(m,1H).
[0222] Compound 19-P2 (179 mg, yield 10.7%) was obtained, retention time: 9.43 min. LCMS: 441.2 [M+1] + . 1HNMR (CDCl3, 400MHz) δ8.45 (d, J = 2.8Hz, 1H), 7.41-7.34 (m, 2H), 7.33-7.29 (m, 1H), 7.26-7. 22(m,2H),7.20-7.16(m,1H),4.89(dd,J=6.4,3.2Hz,1H)4.27(t,J=6.00Hz,1H),3.89-3.68( m,5.5H),3.58-3.51(m,3H),2.57-2.38(m,3H),2.33-2.26(m,1H),2.23-2.14(m,1H),1.96-1 .84(m,3H),1.69-1.83(m,2H),1.46-1.39(m,1H),1.20(t,J=7.00Hz,3H),1.17-1.11(m,1H).
[0223] Compound 19-P3 (189 mg, yield 11.3%) was obtained, retention time: 7.57 min. LCMS: 441.2 [M+1] + . 1 HNMR (CDCl3, 400MHz) δ8.45 (d, J = 2.8Hz, 1H), 7.43-7.29 (m, 3H), 7.26-7.22 (m, 2H), 7.20-7. 16(m,1H),4.89(dd,J=6.4,3.2Hz,1H),4.26(t,J=6.4Hz,1H),3.89-3.68(m,5.5H),3.58-3.5 1(m,3H),2.59-2.51(m,1H),2.48-2.37(m,2H),2.32-2.25(m,1H),2.24-2.14(m,1H),2.03-1 .86(m,3H),1.82-1.67(m,2H),1.46-1.38(m,2H),1.20(t,J=7.00Hz,3H),1.16-1.09(m,1H).
[0224] Compound 19-P4 (314 mg, yield 18.8%) was obtained, retention time: 6.30 min. LCMS: 441.2 [M+1] + . 1HNMR (CDCl3, 400MHz) δ8.45 (d, J = 2.8Hz, 1H) 7.40-7.29 (m, 3H) 7.26-7.20 (m, 2H), 7.15 (d,J=7.00Hz,1H),4.70(t,J=5.2Hz,1H),3.93-3.68(m,6H),3.66-3.58(m,2H),3.55( d,J=9.2Hz,1H),2.58-2.48(m,2H),2.46-2.37(m,2H),2.21-2.13(m,1H),1.98-1.89( m,2H),1.82-1.68(m,3H),1.46-1.38(m,1H),1.24(t,J=7.0Hz,3H),1.19-1.10(m,1H).
[0225] Step 3: Preparation of Compound 19-P2 Hydrochloride
[0226] Dissolve compound 19-P2 (120 mg, 0.272 mmol) in ethyl acetate (5 mL), add dioxane hydrochloride solution (0.14 mL, 4 N), and react at room temperature for 3 h. Filter, collect the filter cake, and dry to obtain compound 19-P2 hydrochloride (140 mg). Use it directly in subsequent experiments. LCMS: 441.2 [M+1] + . 1 H NMR(600MHz, Methanol-d4)δ8.46(d,J=2.9Hz,1H),7.69-7.53(m,2H),7.45-7.25(m,4H),4.97(dd,J=6 .3,4.1Hz,1H),4.74(dd,J=7.5,4.8Hz,1H),3.78-3.65(m,3H),3.64-3.58(m,2H),3.52(qd,J=7.0,1.5 Hz,2H),3.46(d,J=9.3Hz,1H),2.93(td,J=12.5,4.6Hz,1H),2.50-2.37(m,3H),2.34-2.21(m,2H),2.0 2(td,J=12.9,4.5Hz,1H),1.94-1.82(m,3H),1.73-1.68(m,1H),1.34-1.30(m,1H),1.11-1.05(m,4H).
[0227] Referring to the synthesis method of Example 6 (Compound 19), Compounds 7, 14-15 were synthesized:
[0228]
[0229] Example 7: Synthesis of Compound 20
[0230] Synthesis route:
[0231]
[0232] Step 1: Synthesis of compound 20-1
[0233] Dissolve intermediate 3-3 (14.8 g, 38.9 mmol) in anhydrous dioxane (20 mL) and anhydrous methanol (20 mL), then add dioxane hydrochloride (150 mL, 2 M) to the mixture. Stir the reaction solution at 25 ° C for 1 hour. After the reaction is completed by LCMS detection, the reaction solution is concentrated under reduced pressure to obtain intermediate 20-1 hydrochloride (14.93 g, white solid, yield 98.45%). LCMS: 264.2 [M-NH2] + .
[0234] Step 2: Synthesis of compounds 20-2-A and 20-2-B
[0235] The intermediate 20-1 hydrochloride (14.93 g, 38.31 mmol) was dissolved in anhydrous methanol (220 mL), sodium acetate (9.43 g, 114.93 mmol) was added at room temperature, and the reaction solution was stirred at 40°C for 0.5 hours. Then it was cooled to room temperature, 3-ethoxy-6-fluoro-2,3-indan-1-one (11.16 g, 57.46 mmol), acetic acid (7.87 g, 131.01 mmol), sodium cyanoborohydride (12.04 g, 191.55 mmol) were added to the reaction in sequence, and the reaction solution was stirred at 60°C for 12 hours. After the reaction was completed by LCMS, the reaction solution was concentrated under reduced pressure to obtain compound 20. Compound 20 was sequentially subjected to reverse phase column chromatography (C18 column, mobile phase: 0.1% ammonia system and 47-60% acetonitrile) and reverse phase column chromatography (C18 column, mobile phase: 0.1% trifluoroacetic acid system and 15-40% acetonitrile). The fraction was adjusted to pH 9 with 5% potassium carbonate aqueous solution and concentrated under reduced pressure to remove acetonitrile. It was then extracted three times with 100 ml of ethyl acetate, the combined organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a pair of trans 20-2-A (2.8 g, yield 15.94%, yellow oil), HPLC retention time: 1.492 min, LCMS retention time: 0.430 min: 459.3 [M+H] + And a pair of cis-20-2-B (4.6 g, yield 26.19%, yellow oil), HPLC retention time: 1.599 min, LCMS retention time: 0.431 min: 459.3 [M+H] + .
[0236] Step 3: Synthesis of compounds 20-P1, 20-P2, 20-P3, and 20-P4
[0237] 20-2-A (2.8 g, 6.11 mmol) was purified by SFC chiral separation (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [CO2-iPrOH (0.1% NH3H2O)]; B%: 25%, isocratic elution mode) to give 20-P1 (1.13 g, yield 40.36%), retention time = 1.514 min. LCMS: 459.2 [M+H] + . 1 H NMR(400MHz,CHLOROFORM-d)δppm 8.46(d,J=2.8Hz,1H),7.38(dt,J=8.0,2.8Hz,1H),7.35-7.29(m,2H),6.98-6.90(m,1H),6.90-6.85 (m,1H),4.84(dd,J=8,2.8Hz,1H),4.27(t,J=6.4Hz,1H),3.90-3.82(m,2H),3.82-3.78(m,1H),3.78 -3.69(m,2H),3.60-3.48(m,3H),2.56-2.49(m,1H),2.49-2.3(m,2H),2.39-2.31(m,1H),2.25-2.15 (m,1H),1.99-1.84(m,3H),1.83-1.70(m,2H),1.45-1.41(m,1H),1.28(s,2H),1.21(t,J=6.8Hz,3H).
[0238] Compound 20-P2 (1.13 g, yield 40.36%) was obtained. Retention time = 1.616 min. LCMS: 459.2 [M+H] + . 1H NMR(400MHz,CHLOROFORM-d)δppm 8.45(d,J=2.8Hz,1H),7.39(dt,J=8.0,2.8Hz,1H),7.35-7.28(m,2.0H),6.93(dt,J=8.8,2.4Hz,1H), 6.85(dd,J=9.6,2.0Hz,1H),4.82(dd,J=6.4,2.8Hz,1H),4.24(t,J=6.0Hz,1H),3.88-3.80(m,3H),3.8 0-3.63(m,3H),3.57-3.48(m,3H),2.59-2.49(m,1H),2.48-2.38(m,2H),2.36-2.29(m,1H),2.21-2.1 3(m,1H),1.99-1.86(m,3H),1.81-1.67(m,2H),1.45-1.40(m,1H),1.26(s,2H),1.19(t,J=7.2Hz,3H).
[0239] 20-2-B (4.6 g, 10.03 mmol) was purified by SFC chiral separation (chromatographic column: DAICEL CHIRALCEL OX (250 mm*50 mm, 10 um); mobile phase: [CO2-i-PrOH (0.1% NH3H2O)]; B%: 35%, isocratic elution mode) to give 20-P3 (1.21 g, yield 26.30%), retention time = 1.741 min. LCMS: 459.2 [M+H] + . 1 H NMR(400MHz,CHLOROFORM-d)δppm 8.44(d,J=2.8Hz,1H),7.39(dt,J=8.0,2.8Hz,1H),7.34-7.28(m,2H),6.95(dt,J=8.8,2.4Hz, 1H),6.86(dd,J=8.8,2.4Hz,1H),4.65(t,J=5.6Hz,1H),3.90-3.81(m,3H),3.80-3.68(m,3H), 3.64-3.53(m,3H),2.62-2.49(m,2H),2.48-2.36(m,2H),2.21-2.13(m,1H),1.97-1.86(m,2H) ,1.83-1.77(m,1H),1.76-1.67(m,2H),1.44-1.40(m,1H),1.26(s,2H),1.23(t,J=6.8Hz,3H).
[0240] 20-P4 (1.12 g, yield 24.35%) was obtained. Retention time = 1.871 min. LCMS: 459.2 [M+H] + . 1 HNMR(400MHz,CHLOROFORM-d)δppm 8.45(d,J=2.4Hz,1H),7.38(dt,J=8.0,2.8Hz,1H),7.34-7.29(m,2H),6.94(dt,J=8.4,2.4 Hz,1H),6.86(dd,J=8.8,2.4Hz,1H),4.64(t,J=5.4Hz,1H),3.91-3.80(m,4H),3.79-3.68( m,3H),3.66-3.52(m,3H),2.63-2.46(m,2H),2.45-2.38(m,2H),2.23-2.12(m,1H),2.00-1 .88(m,2H),1.83-1.67(m,4H),1.45-1.39(m,1H),1.28-1.25(m,2H),1.23(t,J=6.8Hz,3H).
[0241] Step 4: Synthesis of Compound 20-P1 Maleate
[0242]
[0243] 20-P1 (1.13 g, 2.46 mmol) was dissolved in methyl tert-butyl ether (11 mL), and maleic acid (286 mg, 2.46 mmol) was added at room temperature. The reaction solution was stirred at 25°C for 24 hours. The reaction solution was filtered, and the filter cake was washed three times with 10 ml of methyl tert-butyl ether, collected and dried to obtain compound 20-P1 maleate (1.1 g, yield 77.68%, white solid). LCMS: 459.2 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ=8.68(br s,1H),8.58(d,J=2.8Hz,1H),7.76(dt,J=3.2,8.8Hz,1H),7.62(dd,J=4.0,8.8Hz,1H),7.48 (dd,J=5.6,8.4Hz,1H),7.34-7.19(m,2H),6.02(s,2H),4.93(dd,J=3.6,5.6Hz,1H),4.81(br t,J=6.2Hz,1H),3.76-3.43(m,8H),2.85(dt,J=4.4,12.0Hz,1H),2.46-2.20(m, 5H),1.99-1.80(m,3H),1.73-1.62(m,1H),1.36-1.26(m,1H),1.16-1.04(m,4H).
[0244] Referring to the synthesis method of Example 7 (Compound 20), Compound 52 maleate and Compound 53 were synthesized:
[0245]
[0246]
[0247] Example 8: Synthesis of Compound 21
[0248]
[0249] Synthesis route:
[0250]
[0251] Step 1: Synthesis of compound 21-1
[0252] SM (20 g, 109.18 mmol) was slowly added to trifluoroacetic anhydride (75 mL) at 0°C. The mixture was stirred at 20°C for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain a residue, which was then diluted with ethyl acetate (120 mL). The pH was adjusted to 10 with a 5% potassium carbonate aqueous solution at 0°C, and the solution was separated by extraction. The aqueous phase was collected and washed with 200 ml of ethyl acetate. The obtained aqueous phase was adjusted to pH 3 with a 1N hydrochloric acid aqueous solution, and then extracted with ethyl acetate (300 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain compound 21-1 (27.99 g, white solid, yield 91.84%). 1H NMR(400MHz, DMSO-d6)δ=12.96-11.99(m,1H),9.98(d,J=8.0Hz,1H),7.51-7.38(m,2H) ,7.29-7.14(m,2H),5.27(dt,J=5.9,8.6Hz,1H),3.00-2.89(m,1H),2.88-2.76(m,1H). F NMR (400MHz, DMSO-d6) δ = -114.91, -74.29.
[0253] Step 2: Synthesis of compound 21-2
[0254] 21-1 (27.8 g, 99.57 mmol) was slowly added with SOCl2 (100 mL) at 20°C. The reaction solution was stirred at 80°C for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain intermediate 21-2 (28.7 g, yellow solid, yield 96.84%), which was directly used in the next step.
[0255] Step 3: Synthesis of compound 21-3
[0256] 21-2 (27.0 g, 90.72 mmol) was dissolved in anhydrous DCM (300 mL), AlCl3 (24.19 g, 181.43 mmol) was slowly added, and the reaction solution was stirred at 40°C for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the crude product was slowly added to water (400 mL) at 0°C. The mixture was fully stirred, and the filter cake was collected by filtration and washed with a small amount of water to obtain intermediate 21-3 (14 g, white solid, yield 59.09%). LCMS: retention time = 0.482 min, 260.1 [MH] - .
[0257] Step 4: Synthesis of compound 21-4-A
[0258] 21-3 (14.00 g, 53.60 mmol) was added to anhydrous tetrahydrofuran (150 mL), cooled to 0 ° C, replaced with nitrogen three times, and NaBH4 (9.94 g, 262.66 mmol) was slowly added. The reaction solution was stirred at 20 ° C for 2 hours. After the reaction was completed, the reaction solution was quenched with saturated aqueous ammonium chloride solution (400 mL) at 0 ° C and extracted with ethyl acetate (300 mL × 2). The combined organic layers were washed with saturated aqueous ammonium chloride solution (50 mL), dried over anhydrous sodium sulfate, and filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by reverse phase separation (chromatographic column: Phenomenex luna C18 250*50mm*10um; mobile phase: [water(TFA)-ACN]; gradient: 5%-35% B over 25min. The retention times of the two peaks were rt = 0.541min and rt = 0.560min, respectively). Among them, the retention time was rt = 0.541min for the trans-21-4-A (3.2 g, white solid, yield 22.68%) LCMS: 262.2 [MH] - .
[0259] Step 5: Synthesis of compound 21-5
[0260] Dissolve 21-4-A (3 g, 11.40 mmol) in toluene (30 mL). Add Ag2O (7.92 g, 34.20 mmol) and EtI (3.56 g, 22.80 mmol, 1.82 mL) and stir at 60 ° C for 12 hours. After the reaction is completed, the reaction solution is concentrated under reduced pressure, and the crude product is purified by reverse phase separation (0.1% TFA system and 0-60% acetonitrile) to obtain intermediate 21-5 (1.12 g, white solid, yield 33.74%). LCMS: retention time = 0.820 min, 290.1 [MH] -
[0261] Step 6: Synthesis of compound 21-6
[0262] Dissolve 21-5 (1.10 g, 3.78 mmol) in MeOH (18 mL), add NaOH (2 M, 11.93 mL) aqueous solution, and stir at 40 ° C for 3 hours. After the reaction is completed, dilute with water (100 mL) and extract with EA (100 mL×2). The combined organic layers are washed with saturated ammonium chloride (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 21-6 (730 mg, white solid, yield 99.00%). LCMS: retention time = 0.350 min, 135.2 [M-NH2-C2H5O+H] +
[0263] Step 7: Synthesis of compound 21-P2
[0264] 21-6 (1.03 g, 3.69 mmol) was dissolved in anhydrous methanol (10 mL), and HOAc (221.47 mg, 3.69 mmol) and sodium cyanoborohydride (695.27 mg, 11.06 mmol) were added in sequence and stirred at 20°C for 3 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the crude product was purified by reverse phase separation (0.1% TFA system and 0-40% acetonitrile), and the fraction was diluted with EA (120 mL), and the pH was adjusted to 10 with 5% potassium carbonate aqueous solution at 0°C, and then extracted with EA (100 ml × 3), and the combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain 21-P2 (1.10 g, white solid, yield 65.05%).
[0265]
[0266] Referring to the synthetic route of 21-P2, 21-P4 was synthesized using corresponding chiral raw materials. (179.44 mg, yield 25.63%). LCMS: 527.3 [M+H] + . 1 H NMR(400MHz,CHLOROFORM-d)δppm 8.44(d,J=2.8Hz,1H),7.37(dt,J=8.8,3.2Hz,1H),7.31(dd,J=8.8,4.0Hz,1H),7.11(dd,J=8.8,4.8Hz,1H),7.0 5(dd,J=8.4,2.0Hz,1H),6.92(td,J=8.8,2.4Hz,1H),4.66(t,J=6.0Hz,1H),3.88-3.81(m,3H)3.79-3.67(m,3H) ,3.65-3.54(m,3H),2.60(dt,J=13.2,6.8Hz,1H),2.53-2.37(m,3H),2.17(td,J=10.8,4.8Hz,1H),1.98-1.89(m ,2H),1.82-1.65(m,3H),1.42(ddd,J=12.8,6.0,2.8Hz,2H),1.24(t,J=7.2Hz,3H),1.14(dt,J=13.2,9.2Hz,1H).
[0267] Step 8: Synthesis of compound 21
[0268] 21-P2 (838 mg, 1.83 mmol) was dissolved in methyl tert-butyl ether (15 mL), and maleic acid (213 mg, 1.84 mmol) was added at room temperature. The reaction solution was stirred at 25°C for 24 hours. The reaction solution was filtered, and the filter cake was washed three times with 10 ml of methyl tert-butyl ether, collected and dried to obtain compound 21 (983.1 mg, yield 93.62%). LCMS: 527.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ=8.61(br s,1H),8.59(d,J=3.2Hz,1H),7.76(dt,J=2.8,8.8Hz,1H),7.62(dd,J=4.4,8.8Hz,1H),7. 51(dd,J=5.2,8.4Hz,1H),7.30-7.22(m,2H),6.02(s,2H),4.97(t,J=5.2Hz,1H),4.75(br t,J=5.6Hz,1H),3.76-3.43(m,8H),2.88-2.77(m,1H),2.46-2.22(m,5H),1 .98-1.78(m,3H),1.72-1.62(m,1H),1.35-1.26(m,1H),1.15-1.04(m,4H).
[0269] Example 9: Synthesis of Compound 49 Fumarate
[0270]
[0271] Synthesis route:
[0272]
[0273]
[0274] Step 1: Synthesis of compound 49-1
[0275] SM1 (16 g, 107.99 mmol, 1 eq) was dissolved in anhydrous tetrahydrofuran (160 mL) to replace nitrogen protection, and isopropylmagnesium chloride (2M, 161.99 mL, 3 eq) was added dropwise to the above reaction solution at 0 ° C. After the addition was completed, the temperature was raised to 25 ° C and reacted for 5 hours. Spot plate detection After the reaction of the raw materials was completed, the reaction solution was slowly poured into a white bucket containing 6N ice HCl (300 mL) for quenching. After quenching, it was extracted with ethyl acetate (100 mL × 3), the organic phases were combined, the organic phases were washed with saturated brine (100 mL), the organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column (petroleum ether: ethyl acetate = 5:1) to obtain compound 49-1 (10.6 g, yellow oil, yield: 45.95%). 1 H NMR(400MHz,CHLOROFORM-d)δ=7.30-7.27(m,1H),7.27-7.25(m,1H),7.23-7.17(m,1H),7.17-7.13(m,2H ),2.92-2.76(m,2H),2.67-2.57(m,1H),1.92-1.77(m,1H),0.94(d,J=6.8Hz,3H),0.76(d,J=6.4Hz,3H).
[0276] Step 2: Synthesis of compound 49-2
[0277] 49-1 (9 g, 46.81 mmol, 1 eq) was added to thionyl chloride (11.14 g, 93.63 mmol, 6.80 mL, 2 eq) to dissolve, and then stirred at 75 ° C for 2 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The product was dissolved in anhydrous dichloromethane (120 mL), and aluminum chloride (6.83 g, 51.26 mmol, 2.80 mL, 1.2 eq) was added in batches at 0 ° C. After the addition was completed, the reaction was carried out at 25 ° C for 12 hours. After the reaction was completed by TLC spot plate detection, the reaction solution was poured into ice water (200 mL) for quenching. After quenching, it was extracted with dichloromethane (80 mL×3), and the organic phases were combined. The organic phase was washed with saturated brine (100 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by normal phase silica gel column (petroleum ether: ethyl acetate = 95:5) to obtain compound 49-2 (6.2 g, red oil, yield: 83.30%). 1H NMR (400MHz, CHLOROFORM-d) δ = 7.74 (d, J = 8.0Hz, 1H), 7.63-7.57 (m, 1H), 7.51 (d, J = 8.0Hz, 1H), 7.38 (t, J = 7.6Hz, 1H), 3.48- 3.35(m,1H),2.66(dd,J=1.2,8.0Hz,1H),2.53-2.41(m,1H),2.36-2.19(m,1H),1.03(d,J=6.4Hz,3H),0.67(d,J=6.8Hz,3H).
[0278] Step 3: Synthesis of compounds 49-3A and 49-3B
[0279] 49-2 (6.2 g, 35.58 mmol, 1 eq) was purified by chiral separation (column: (S, S) Whelk-O1 50*4.6 mmI.D., 3.5 um; mobile phase: mobile phase A: CO2, mobile phase B: IPA (0.05% DEA); method: IPA (0.05% DEA) in CO2 from 5% to 40%, flow rate: 3 mL / min; detector: PDA; column temperature: 35°C; pressure: 100 Bar) to obtain intermediate 49-3A (2.9 g, red oil, yield: 46.77%) and intermediate 49-3B (2.9 g, red oil, yield: 46.77%).
[0280] Step 4: Synthesis of compounds 49-P1 and 49-P2
[0281] 49-3A (402.38 mg, 2.31 mmol, 1 eq), intermediate 20-1 (0.9 g, 2.31 mmol, 1 eq, 3 HCl), sodium acetate (757.78 mg, 9.24 mmol, 4 eq) and acetic acid (416.04 mg, 6.93 mmol, 396.61 μL, 3 eq) were dissolved in anhydrous methanol (10 mL) and sodium cyanoborohydride (725.62 mg, 11.55 mmol, 5 eq) was added. The whole reaction system was reacted at 25 ° C for 4 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure by LCMS detection. The crude product was purified by reverse phase separation (0.1% ammonia system and acetonitrile) and freeze-dried to obtain a crude product (0.5 g, yellow oil, yield 48.53%). LCMS: retention time = 0.436 min, 439.3 [M + H] +. The free compound corresponding to compound 49-P1 (280 mg, yellow oil, yield: 54.88%) was obtained by chiral separation and purification [carbon dioxide-isopropanol system (0.1% ammonia water): 25%]. The free compound corresponding to compound 49-P1 (280 mg, 638.43 μmol, 1 eq) was dissolved in 4-methyl-2-pentanone (2.8 mL), and fumaric acid (74.10 mg, 638.43 μmol, 1 eq) was added and stirred at 25°C for 12 hours. The precipitated white precipitate was filtered, and the filter cake was rinsed with 4-methyl-2-pentanone (3 mL). The upper filter cake obtained was the fumarate of compound 49-P1 (352 mg, white solid, yield: 98.21%). LCMS, 439.3 [M+H] + . 1 H(400MHz, METHANOL-d4)δ=8.52(t,J=1.6Hz,1H),7.67-7.59(m,2H),7.37(t,J=8.0Hz,2H),7.33-7.23(m,2H),6.68(s,2 H),4.59(t,J=8.4Hz,1H),3.85-3.79(m,2H),3.75(d,J=9.2Hz,1H),3.70(dd,J=4.4,9.2Hz,2H),3.56(d,J=9.2Hz,1H),3 .21(s,1H),3.20-3.12(m,1H),3.08-2.99(m,1H),2.62-2.48(m,3H),2.45-2.33(m,2H),2.30-2.18(m,1H),1.98-1.73(m ,3H),1.66-1.52(m,1H),1.45-1.36(m,1H),1.19(s,1H),1.19-1.12(m,1H),1.08(d,J=6.8Hz,3H),0.77(d,J=6.8Hz,3H)
[0282] The free compound corresponding to compound 49-P2 (110 mg, yellow oil, yield: 21.56%) was obtained. The free compound corresponding to compound 49-P2 (110 mg, 250.81 μmol, 1 eq) was dissolved in 4-methyl-2-pentanone (1.1 mL), and fumaric acid (29.11 mg, 250.81 μmol, 1 eq) was added and stirred at 25°C for 12 hours. The precipitated white precipitate was filtered, and the filter cake was rinsed with 4-methyl-2-pentanone (2 mL). The upper filter cake obtained was the fumarate of compound 49-P2 (136 mg, white solid, yield: 97.76%) LCMS, 439.3 [M+H] + . 1H NMR (A42-B) (400MHz, METHANOL-d4) δ = 8.49 (d, J = 2.4Hz, 1H), 7.70-7.54 (m, 2H), 7.45-7.21 (m, 4H), 6.65 ( s,2H),4.66(dd,J=4.0,8.0Hz,1H),3.82-3.66(m,5H),3.55(d,J=9.2Hz,1H),3.43-3.34(m,1H),3.21(s,1 H),2.98(dt,J=4.4,12.4Hz,1H),2.60-2.42(m,3H),2.30-2.13(m,2H),2.12-1.96(m,2H),1.94-1.84(m, 2H),1.81-1.71(m,1H),1.44-1.36(m,1H),1.22-1.13(m,2H),0.99(d,J=6.8Hz,3H),0.67(d,J=6.8Hz,3H)
[0283] Step 5: Synthesis of compounds 49-P3 and 49-P4
[0284] 49-3-B (402.38 mg, 2.31 mmol, 1 eq), intermediate 20-1 (0.9 g, 2.31 mmol, 1 eq, 3 HCl), sodium acetate (757.78 mg, 9.24 mmol, 4 eq) and acetic acid (416.04 mg, 6.93 mmol, 396.61 μL, 3 eq) were dissolved in anhydrous methanol (10 mL) and sodium cyanoborohydride (725.62 mg, 11.55 mmol, 5 eq) was added. The whole reaction system was reacted at 25 ° C for 4 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure by LCMS detection. The crude product was purified by reverse phase separation (0.1% ammonia system and acetonitrile) and freeze-dried to obtain a crude product (0.55 g, yellow oil, yield 53.49%). LCMS: retention time = 0.450 min, 439.2 [M+H] +. Chiral separation and purification [carbon dioxide-isopropanol system (0.1% ammonia water): 27%] gave the corresponding free compound of compound 49-P3 / 49-P4 (120 mg, yellow oil, yield: 23.52%). The obtained compound 49-P3 / corresponding free compound (120 mg, 273.61 μmol, 1 eq) was dissolved in 4-methyl-2-pentanone (1.2 mL), and fumaric acid (31.76 mg, 273.61 μmol, 1 eq) was added and stirred at 25°C for 12 hours. The precipitated white precipitate was filtered, and the filter cake was rinsed with 4-methyl-2-pentanone (3 mL). The upper filter cake obtained was the fumarate of compound 49-P3 (150 mg, white solid, yield: 98.48%). LCMS, 439.3 [M+H] + . 1 H NMR (400MHz, METHANOL-d4) δ = 8.54-8.46 (m, 1H), 7.64-7.58 (m, 2H), 7.37 (t, J = 5.2Hz, 2H), 7.33-7.25 (m, 2H), 6. 68(s,2H),4.63(t,J=8.4Hz,1H),3.87-3.66(m,5H),3.56(d,J=9.2Hz,1H),3.20-3.12(m,1H),3.03(dt,J=5.2,1 2.4Hz,1H),2.61-2.48(m,3H),2.45-2.33(m,2H),2.16-1.96(m,2H),1.92(d,J=13.6Hz,1H),1.85-1.72(m,1H), 1.63-1.51(m,1H),1.41(td,J=4.6,13.4Hz,1H),1.19-1.13(m,1H),1.07(d,J=6.8Hz,3H),0.76(d,J=6.8Hz,3H).
[0285] The free compound corresponding to compound 49-P4 (380 mg, yellow oil, yield: 74.48%) was obtained. The free compound corresponding to compound 49-P4 (380 mg, 866.44 μmol, 1 eq) was dissolved in 4-methyl-2-pentanone (3.8 mL), and fumaric acid (100.57 mg, 866.44 μmol, 1 eq) was added and stirred at 25°C for 12 hours. The precipitated white precipitate was filtered, and the filter cake was rinsed with 4-methyl-2-pentanone (5 mL). The upper filter cake obtained was the fumarate of compound 49-P4 (470 mg, white solid, yield: 97.80%). LCMS, 439.3 [M+H] + . 1H NMR(A42-D)(400MHz, METHANOL-d4)δ=8.54-8.46(m,1H),7.64-7.58(m,2H),7.37(t,J=7.6Hz,2H),7.33-7.25(m,2H) ,6.68(s,2H),4.63(t,J=8.4Hz,1H),3.87-3.66(m,5H),3.56(d,J=9.2Hz,1H),3.21(s,1H),3.20-3.12(m,1H),3.03(d t,J=5.2,12.4Hz,1H),2.61-2.48(m,3H),2.45-2.33(m,2H),2.16-1.96(m,2H),1.92(d,J=13.6Hz,1H),1.85-1.72(m, 1H), 1.57 (td, J = 9.6, 12.4Hz, 1H), 1.45-1.34 (m, 1H), 1.23-1.13 (m, 2H), 1.07 (d, J = 6.8Hz, 3H), 0.76 (d, J = 6.8Hz, 3H).
[0286] Example 10: Synthesis of Compound 50
[0287] Synthesis route:
[0288]
[0289] Step 1: Synthesis of compound 50-1
[0290] SM2 (900 mg, 3.84 mmol, 1 eq) and pyridine (911.55 mg, 11.52 mmol, 3 eq) were added to anhydrous dichloromethane (10 mL). The reaction solution was protected with nitrogen and the reaction solution was cooled to 5 ° C. Then trifluoroacetic anhydride (887.48 mg, 4.23 mmol, 587.35 μL, 1.1 eq) was slowly added dropwise at 5 ° C, and the total addition time was 20 minutes. After the addition was completed, the reaction was continued at 5 ° C for 10 minutes. LCMS detected that the reaction was complete, and the reaction solution was directly concentrated. After concentration, it was purified by a reverse phase column (C18 column, 0.1% formic acid aqueous solution) and directly lyophilized to obtain 50-1 (400 mg, white solid, yield 31.53%). LCMS: 353.0 [M + Na] + .
[0291] Step 2: Synthesis of compound 50-2
[0292] 50-1 (400 mg, 1.21 mmol, 1 eq) was added to anhydrous dichloromethane (9 mL), and then trifluoroacetic acid (3 mL) was added to the reaction solution. The reaction solution was stirred at 20 ° C for 1 hour. LCMS detected that the reaction was complete. The reaction solution was directly concentrated. After concentration, it was purified by reverse phase column (C18 column, 0.1% hydrochloric acid aqueous solution) and lyophilized to obtain 50-2 (300 mg, white solid, yield 92.90%). LCMS: 231.0 [M+H] + .
[0293] Step 3: Synthesis of compound 50-3
[0294] 50-2 (300 mg, 1.13 mmol, 1 eq, HCl), formaldehyde aqueous solution (273.91 mg, 3.38 mmol, 251.29 μL, 37% purity, 3 eq) and sodium acetate (92.29 mg, 1.13 mmol, 1 eq) were added to anhydrous methanol (5 mL) in sequence and stirred evenly. Then sodium cyanoborohydride (282.81 mg, 4.50 mmol, 4 eq) was added to the mixture. The reaction solution was stirred at 20°C for 1 hour. LCMS detected that the reaction was complete. The reaction solution was directly concentrated. After concentration, it was purified by reverse phase column (C18 column, 0.1% hydrochloric acid aqueous solution) and lyophilized to obtain 50-3 (315.78 mg, yellow oil, yield 99.40%). LCMS: 245.1 [M+H] + .
[0295] Step 4: Synthesis of compound 50-4
[0296] 50-3 (315.78 mg, 1.13 mmol, 1 eq, HCl) was added to methanol (5 mL), and aqueous sodium hydroxide solution (2 M, 5 mL, 8.89 eq) was added to the reaction solution. The reaction solution was stirred at 40 ° C for 1 hour. After the reaction was completed by LCMS detection. The reaction solution was cooled to room temperature, diluted with 5 ml of water, and the mixed solution was extracted with ethyl acetate (5 mL × 3). The crude product was purified by reverse phase column chromatography (C18 column, 0.1% hydrochloric acid aqueous solution). Then the pH was adjusted to 7 with solid sodium bicarbonate and extracted three times with 300 ml of dichloromethane. Drying and concentration gave 50-4 (150 mg, yellow oil, yield 89.96%). LCMS: 516.3 [M + H] + .
[0297] Step 5: Synthesis of compounds 50-P1 and 50-P2
[0298] 50-4 (50 mg, 337.37 μmol, 1 eq) and intermediate 1-3 (94.23 mg, 337.37 μmol, 1 eq) were added to anhydrous dichloromethane (2 mL) in sequence, and then sodium acetate borohydride (214.51 mg, 1.01 mmol, 3 eq) was added to the mixture. The reaction solution was stirred at 20 ° C for 1 hour. LCMS detected that the reaction was complete. The reaction solution was directly concentrated to obtain a crude product and a residue (i.e., compound 50). After concentration, it was filtered through a reverse phase column (C 18 The racemate was purified by chiral preparation (chromatographic column: DAICEL CHIRALPAK AD (250mm*30mm, 10um); mobile phase: [CO2-iPrOH (0.1% NH3H2O)]; B%: 25%, isocratic elution mode). After freeze-drying, 50-P1 (13.5mg, yellow oil, yield 9.31%) was obtained, retention time = 1.668min, LCMS: 412.1 [M+H] + . 1 H NMR (400MHz, CHLOROFORM-d) δ = 8.45 (d, J = 2.8Hz, 1H), 7.37 (td, J = 8.4, 2.8Hz, 1H), 7.33 (dd, J = 8.8, 4.4Hz, 1H), 7.14 (t, J=8.2Hz,1H),6.99(d,J=7.6Hz,1H),6.65(t,J=7.4Hz,1H),6.50(d,J=8.0Hz,1H),4.02-3.99(m,1H),3.88-3.69(m,5H) ,3.55(d,J=9.2Hz,1H),3.23(dd,J=9.2,7.2Hz,1H),3.04(dd,J=9.6,3.6Hz,1H),2.72(s,3H),2.54(dt,J=11.2,5.2Hz, 1H),2.47-2.36(m,2H),2.20-2.08(m,1H),2.00-1.86(m,2H),1.82-1.62(m,2H),1.42-1.39(m,2H),1.18-1.10(m,1H).
[0299] 50-P2 (16.6 mg, yellow oil, yield 11.10%) was obtained. Retention time = 1.795 min, LCMS: 412.1 [M+H] + . 1H NMR (400MHz, CHLOROFORM-d) δ = 8.43 (d, J = 2.8Hz, 1H), 7.37 (td, J = 8.4, 2.8Hz, 1H), 7.30 (dd, J = 8.8, 4.2Hz, 1H), 7.14 (td, J =8.2,1.2Hz,1H),7.00(d,J=7.6Hz,1H),6.65(td,J=7.2,1.2Hz,1H),6.50(d,J=8.0Hz,1H),4.02-3.99(m,1H),3.88-3.69( m,5H),3.55(d,J=9.2Hz,1H),3.23(dd,J=9.6,7.2Hz,1H),3.04(dd,J=9.4,3.8Hz,1H),2.72(s,3H),2.54(dt,J=10.8,5.2 Hz,1H),2.45-2.36(m,2H),2.23-2.16(m,1H),1.92-1.85(m,2H),1.81-1.72(m,2H),1.44-1.39(m,1H),1.18-1.10(m,1H).
[0300] Example 11: Synthesis of Compound 51
[0301] Synthesis route:
[0302]
[0303] Step 1: Synthesis of compound 51
[0304] The hydrochloride of intermediate 20-1 (810 mg, 2.08 mmol) was added to acetonitrile (28 mL) to replace nitrogen three times, and DIEA (1.34 g, 10.39 mmol) and m-chlorobenzoyl chloride (291 mg, 1.66 mmol) were added at 0°C, and the mixture was reacted at 25°C for 1 hour. After the reaction, the reaction solution was filtered and concentrated under reduced pressure, and the crude product was purified by reverse phase separation (0.1% ammonia system and 20-50% acetonitrile) to obtain compound 51 (264 mg, milky white solid, yield 30.32%). LCMS: 419.1 [M+H] + . 1H NMR(400MHz,CHLOROFORM-d)δ=8.16(t,J=1.75Hz,1H),7.27(t,J=1.81Hz,1H),7.23- 7.13(m,2H),7.11-7.01(m,3H),5.69-5.37(m,1H),3.65-3.60(m,5H),3.31-3.21(d,J =9.2Hz1H),3.14-3.00(m,1H),2.83-2.63(m,1H),2.30-2.08(m,2H),1.89-1.75(m,1 H), 1.62 (d, J = 13.60Hz, 1H), 1.69-1.48 (m, 2H), 1.46-1.05 (m, 1H), 0.91-0.74 (m, 1H).
[0305] Test Example 1. MOR cAMP agonist activity
[0306] 1.1 Experimental purpose: To test the cAMP agonist activity of the compounds of the present invention on human μ subtype opioid receptor (hMOR).
[0307] 1.2 Experimental steps:
[0308] 1.2.1 Compound preparation
[0309] a. The test compound and DAMGO (enkephalin) were dissolved in DMSO to a stock concentration of 200 μM.
[0310] b. Prepare sample dilution series on 384-well LDV plates. 3.162-fold serial dilution, total 9 concentration points.
[0311] c. Use the Echo machine to transfer the sample dilution series to the assay plate (Corning-3824), with 50 nL transferred to each well.
[0312] d. Use the Echo machine to transfer 50 nL of 333 μM DAMGO (as a positive control well) and 50 nL of DMSO (as a negative control well) to the corresponding positions of the experimental plate.
[0313] 1.2.2 MOR cAMP agonist activity assay
[0314] The experiment used the cAMP detection kit of Cisbio (Cisbio#62AM4PEJ).
[0315] a. Prepare the assay buffer (Assay Buffer) and stimulation buffer (STB) required for the experiment.
[0316] Assay buffer: 1× HBSS (+ / +) (Invitrogen #14025-126) 20 mM;
[0317] Stimulation buffer: prepared with assay buffer, containing 5 μM NKH477 (CAS: 138605-00-2) and 200 μM IBMX (3-isobutyl-1-methylxanthine);
[0318] In a 10 μL reaction system, the final concentration of IBMX was 100 μM, and the final concentration of NKH477 was 2 μM.
[0319] b. First, add 5 μL of stimulation buffer to each well of the experimental plate (50 nL of compound in the well), and then add 5 μL of CHO-K1 / hMOR cell suspension. The number of cells in the well is 10,000 / well.
[0320] c. Place the test plate in a 37°C constant temperature incubator for 40 minutes.
[0321] d. Prepare a cAMP standard concentration curve. The first concentration point is 2848nM, and the concentration is diluted 4 times, with a total of 16 test concentrations. Each concentration point is repeated 3 times.
[0322] e. The Cisbio cAMP detection kit comes with d2-labeled cAMP reagent (d2 reagent) and Eu-labeled cAMP antibody reagent (Crypate reagent). Prepare the two reagents according to the kit instructions and add them to the sample test plate and cAMP standard concentration test plate respectively. Each well must first add 5μL d2 reagent, then add 5μL Cryptateagent.
[0323] f. The test plate was left at room temperature for 60 minutes and then read on Envision.
[0324] 1.3 Test Results
[0325] The cAMP agonist activity of the compounds of the present invention on human μ subtype opioid receptor (hMOR) EC 50 and E max See Table 1, E max The maximum effect of the compound at the tested concentration on the change in cAMP level (the maximum effect of enkephalin DAMGO is 100%).
[0326] Table 1 MOR cAMP activity test results
[0327]
[0328] 1.4 Test conclusion
[0329] The compound of the present invention has a significant agonistic effect on the μ receptor cAMP signaling pathway.
[0330] Experimental Example 2. β-arrestin-2 agonist activity test
[0331] 2.1 Experimental purpose: To test the β-arrestin-2 agonist activity of the compounds of the present invention on human μ subtype opioid receptor (hMOR).
[0332] 2.2 Experimental steps:
[0333] 2.2.1 Compound preparation
[0334] a. All samples were dissolved in DMSO to a stock concentration of 10 mM.
[0335] b. Prepare sample dilution series on 384-well LDV plates. 3.162-fold serial dilution, totaling 11 concentration points.
[0336] c. Use the Echo machine to transfer the sample dilution series to the assay plate, transferring 60 nL per well corresponding to the compound.
[0337] d. Use the Echo machine to transfer 60 nL of 3.33 mM DAMGO (as HPE) and 60 nL of DMSO (as ZPE) to the corresponding positions of the experimental plate.
[0338] 2.2.2 Experimental procedures for MORβ-arrestin-2 agonist activity
[0339] The experiment used the PathHunter detection kit from DiscoveRX (DiscoveRX#93-0213C3)
[0340] a. Prepare the assay buffer and PathHunter detection reagent required for the experiment
[0341] Assay Buffer: 1×DPBS buffer
[0342] PathHunter Detection Reagents: The kit comes with three components. According to the kit instructions, mix Galacton Star, Emerald II and PathHunter Cell Assay Buffer in a ratio of 1:5:19 to prepare the detection reagent.
[0343] b. Add 20 μL of MORβ-arrestin-2 cell suspension to each well of the experimental plate (wells already containing compounds), with the number of cells in each well being 7500 / well.
[0344] c. Centrifuge at 300 rpm for 30 seconds and incubate at room temperature for 2 hours.
[0345] d. Add 6 μL of PathHunter detection reagent to each well of the experimental plate.
[0346] e. The test plate was centrifuged at 300 rpm for 30 seconds and then allowed to stand at room temperature for 60 minutes before reading on Envision.
[0347] 2.3 Test Results
[0348] The EC of the compounds of the present invention for the β-arrestin-2 agonist activity of human μ subtype opioid receptor (hMOR) 50 and E max See Table 2, E max The maximum effect of the compound at the tested concentration on the change in cAMP level (the maximum effect of enkephalin DAMGO is 100%).
[0349] Table 2 MORβ-arrestin-2 activity test results
[0350]
[0351] *The compound has no actual agonist activity within the concentration range tested, and the calculated percentage of action fluctuates randomly within a small range around 0. Therefore, in this experiment, EC 50 All concentrations were recorded as being greater than the highest concentration detected (>10000 nM), and agonism was recorded as being approximately 0%.
[0352] 2.4 Conclusion
[0353] The compound of the present invention has no stimulating effect on the μ receptor β-arrestin-2 signal pathway, or has a weak stimulating effect.
[0354] Test Example 3. Evaluation of metabolic stability of liver microsomes
[0355] 1. Test materials: Liver microsomes: rat liver microsomes, Beagle dog liver microsomes, human liver microsomes
[0356] 2. Test reagents: reduced nicotinamide adenine dinucleotide phosphate (NADPH), Roche Diagnostics GmbH; magnesium chloride, Sigma-aldrich; phosphate buffered saline (PBS) pH=7.4, Sigma; acetonitrile, Merck Chemical; methanol, Merck Chemical; formic acid, Sigma; testosterone, Aladdin; tolbutamide, Sigma.
[0357] 3. Experimental instruments: water purifier, Millipore; electronic balance, METTLER TOLEDO; high-speed desktop centrifuge, Thermo; water bath constant temperature oscillator, Shanghai Yiheng Technology Co., Ltd.; vortex oscillator, Thermo; LC-MS / MS, ABSCIEX.
[0358] 4. Experimental method: The metabolic stability of the test substance was evaluated using SD rats, Beagle dogs and human liver microsomes. The test substance was incubated with liver microsomes of different species supplemented with NADPH in a 37°C water bath. At the specified time point, a cold acetonitrile solution (or other organic solvent) containing an internal standard was added to terminate the reaction. The sample was pre-treated and entered into LC-MS / MS for semi-quantitative analysis. The retention time of the analyte and the internal standard, the chromatogram acquisition and the integration of the chromatogram were processed using the software Analyst (AB Sciex, Framingham, Massachusetts, USA). The in vitro elimination rate constant ke of the sample was obtained by converting the ratio of the sample to the internal standard peak area into a residual percentage, and the in vitro clearance rate and half-life of the test substance were calculated. The results are shown in Table 2.
[0359] 5. Test results:
[0360] The metabolic stability of the compounds of the present invention to liver microsomes is shown in Table 3.
[0361] Table 3 Metabolic stability of the compounds of the present invention in liver microsomes
[0362]
[0363]
[0364] Conclusion: In rat liver microsomes, compound 11 hydrochloride, compound 19-P2, compound 21-P2, and compound 21-P4 were cleared at a medium rate, and the other compounds were cleared at a high rate; in dog liver microsomes, compound 11 hydrochloride and compound 21-P2 hydrochloride were cleared at a low rate, compound 19-P4, compound 20-P4, and compound 21-P4 were cleared at a high rate, and the other compounds were cleared at a medium rate; in human liver microsomes, compound 11 hydrochloride and compound 19-P2, compound 20-P1, and compound 21-P2 were cleared at a medium rate, and the other compounds were cleared at a high rate.
[0365] Test Example 4. Permeability and transporter substrate evaluation
[0366] 1. Test cells: Caco-2 cells
[0367] 2. Experimental reagents: Hank's balanced salt solution, Gibco; 4-hydroxyethylpiperazineethanesulfonic acid, Gibco; fetal bovine serum, Corning; fluorescent yellow, Sigma-Aldrich; dimethyl sulfoxide, J&K Scientific LTD; acetonitrile, Merck Chemical; MEM medium, Gibco; non-essential amino acids, Gibco.
[0368] Instruments: water purifier, ELGA LabWate; biological safety cabinet, NUAIRE; constant temperature CO2 incubator, Thermo; microplate reader, PerkinElmer;
[0369] LC-MS / MS, AB SCIEX.
[0370] 3. Experimental method: The Caco-2 monolayer cell model was used to determine the bidirectional permeability of the analyte and evaluate whether it was transported out of the transporter. In the experiment, Caco-2 cells were inoculated into 96-well cell culture plates and used for transport experiments after continuous culture for 28 days. The analyte was administered bidirectionally. After incubation for 120 minutes, samples from the top A and the base B were collected, and the content of the analyte in the sample was semi-quantitatively determined by liquid chromatography tandem mass spectrometry (LC / MS / MS). The apparent permeability coefficient (Papp) and the excretion rate in the apical to base (AB) direction and the base to apical (BA) direction were calculated according to the concentration of the analyte. The results are shown in Table 4 below.
[0371] Table 4 Permeability results of the compounds of the present invention in Caco-2 cells
[0372]
[0373] Conclusion: All compounds of the present invention are hypertonic.
[0374] Experimental Example 5: In vivo pharmacokinetics study of compounds
[0375] 1. Test materials:
[0376] Animals: SD rats and Beagle dogs, 3 in each group. SD rats weigh 200-250g, Beagle dogs weigh about 12kg.
[0377] Reagents: acetonitrile, MERCK; methanol, MERCK; formic acid, Sigma; tolbutamide, Sigma.
[0378] Instruments: water purifier, Millipore; electronic balance, METTLER TOLEDO; high-speed desktop centrifuge, Thermo; water bath constant temperature oscillator, Shanghai Yiheng Technology Co., Ltd.; vortex oscillator, Thermo; LC-MS / MS, AB SCIEX.
[0379] 2. Test methods:
[0380] After the hydrochloride of compound 1, compound 2, compound 11 and compound 19-P2 was dissolved with DMSO and Solutol, the intravenous dose of rats was 1 mg / kg, the oral dose of rats was 10 mg / kg, the intravenous dose of dogs was 0.2 mg / kg, and the oral dose was 1 mg / kg (the doses were all calculated as free base). Whole blood was collected before administration, 5min (intravenous), 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h, and 24h. The whole blood was placed in a heparinized EP tube and centrifuged at 13500rpm for 10min to separate the plasma. After pretreatment, the plasma was analyzed by LC-MS / MS to determine the concentration of the analyte in the plasma and calculate the pharmacokinetic parameters.
[0381] 3. Test results:
[0382] The results are shown in Tables 5-7 below:
[0383] Table 5 Pharmacokinetic parameters of compound 1 after oral administration (10 mg / kg) to SD rats
[0384]
[0385] Table 6 Pharmacokinetic parameters of SD rats after intravenous (1 mg / kg) and oral administration (10 mg / kg)
[0386]
[0387]
[0388] Table 7 Pharmacokinetic parameters of compound 11 after intravenous (0.2 mg / kg) and oral gavage (1 mg / kg) administration to Beagle dogs
[0389]
[0390] Conclusion: Compound 19-P2 hydrochloride showed relatively high bioavailability in rats and dogs.
[0391] Experimental Example 6 In vivo pharmacodynamic study of compound 20-P1 maleate salt
[0392] 1. Experimental purpose: The rat hot plate method was used to test the effect of compound 20-P1 maleate on the pain threshold of rats.
[0393] 2. Test materials:
[0394] Experimental animals: Female SD rats, 200±20g;
[0395] Test instruments: Panlab hot plate instrument, electronic balance.
[0396] 3. Experimental Grouping and Drug Administration
[0397] Thirty female SD rats (10 rats / group) were divided into three groups according to the basic pain threshold: Group 1 was a vehicle control group (ultrapure water), Group 2 was a 0.45 mg / kg compound 20-P1 maleate group, and Group 3 was a 10 mg / kg oxycodone group. A single intragastric administration was performed with a volume of 10 mL / kg (see Table 8).
[0398] Table 8 Experimental groups and drug administration
[0399]
[0400] 4. Test methods
[0401] The day before administration, the basic pain threshold of rats was measured by hot plate instrument. Each rat was measured 3 times, with a test interval of not less than 10 minutes. The average of the 3 measurements was taken as the basic pain threshold of each rat. The measurement temperature was 55°C, and the measurement time was limited to 20 seconds to avoid scalding the soles of the rats. Rats were grouped according to their average basic pain threshold.
[0402] The next day, the time-effect relationship test of the analgesic effect of the test substance was carried out. 0.5, 1, 2, and 4 hours after the rats were intragastrically administered, the latency of the pain threshold reaction of the rats was measured, and the maximum analgesic rate (Maximum Possible Effect, MPE%) of each rat was calculated with 20s as the limit: MPE% = [(pain threshold after administration - average basal pain threshold) / (20 - pain threshold before administration)] × 100%.
[0403] 5. Collection and Statistical Analysis
[0404] The experimental data were expressed as Mean ± SEM, and Graphpad prism 8.0 was used to perform Student's t-test to compare the differences among the groups. p < 0.05 was considered to be a significant difference, and p < 0.01 was considered to be a very significant difference.
[0405] 6. Results and Analysis
[0406] The results showed that compared with oxycodone, the maleate salt of the compound 20-P1 of the present invention had better analgesic efficacy at a lower dose, and the analgesic effect lasted longer (see Table 9 for details).
[0407] Table 9 Maximum analgesic rate at different times after compound administration (MPE%, Mean ± SEM, n = 10)
[0408]
[0409] Note: Compared with the oxycodone group, * p<0.05, ** p<0.01.
Claims
1. A compound represented by formula (II), a pharmaceutically acceptable salt or stereoisomer thereof: in: Ring A is X 1a Selected from: C(R 1a )2. NR 1a or O; X 1b Selected from: C(R 1b )2. NR 1b or O; X2 is selected from: CR2 or N; X3 is selected from: CR3 or N; X4 is selected from: CR4 or N; X5 is selected from: CR5 or N; X6 is selected from: CH or N; Y is selected from a bond or -(C=O)-; Each R 1a and R 1b Each independently selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, the C 1-6 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkyl C(=O)NH-, C 1-6 Alkyl NHC(=O)-, or C 1-6 Alkylamino substituted; R1, R2, R3, R4, R5 are each independently selected from: H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkyl C(=O)-, C 1-6 Haloalkyl C(=O)-, (C 1-6 Alkyl)2N-, (C 1-6 alkyl) 2NC(=O)-, cyano, the C 1-6 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-6 Alkoxy, C 1-6 Haloalkoxy, or (C 1-6 alkyl) 2N-substituted; R6, R 7a , R 7b , R 7c , R 7d Each independently selected from: H, or halogen; Provided that: the compound of formula (II), its pharmaceutically acceptable salt or stereoisomer does not include:
2. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, characterized in that The compound represented by formula (IIA), its pharmaceutically acceptable salt or stereoisomer: in: Ring A is X 1a Selected from: C(R 1a )2. NR 1a or O; X 1b Selected from: C(R 1b )2. NR 1b or O; X2 is selected from: CR2 or N; X3 is selected from: CR3 or N; X4 is selected from: CR4 or N; X5 is selected from: CR5 or N; X6 is selected from: CH or N; Y is selected from a bond or -(C=O)-; Each R 1a and R 1b Each independently selected from: H, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 3-6 Cycloalkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, the C 1-6 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkyl C(=O)NH-, C 1-6 Alkyl NHC(=O)-, or C 1-6 Alkylamino substituted; R1, R2, R3, R4, R5 are each independently selected from: H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy, C 1-6 Alkyl C(=O)-, C 1-6 Haloalkyl C(=O)-, (C 1-6 Alkyl)2N-, (C 1-6 alkyl) 2NC(=O)-, cyano, the C 1-6 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-6 Alkoxy, C 1-6 Haloalkoxy, or (C 1-6 alkyl) 2N-substituted; R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, or halogen.
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Ring A is:
4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Each R 1a or R 1b Each independently selected from: H, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 3-6 Cycloalkoxy, C 1-3 Alkylamino, C 1-3 Alkylthio, the C 1-3 The terminal carbon atom of the alkoxy group is optionally replaced by a C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Alkyl C(=O)NH-, C 1-3 Alkyl NHC(=O)-, or C 1-3 substituted by alkylamino; preferably H, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, pentachloroethoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, methylamino, ethylamino, methylthio or ethylthio, the methoxy, ethoxy, n-propoxy, isopropoxy The terminal carbon atom of the radical is optionally substituted by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, CH3C(=O)NH-, CH3CH2C(=O)NH-, CH3NHC(=O)-, CH3CH2NHC(=O)-, methylamino, or ethylamino.
5. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R1, R2, R3, R4, R5 are each independently selected from: H, halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy, C 1-3 Alkyl C(=O)-, C 1-3 Haloalkyl C(=O)-, (C 1-3 Alkyl)2N-, (C 1-3 alkyl) 2NC(=O)-, cyano, the C 1-3 The terminal carbon atom of the alkyl group is optionally replaced by a C 1-3 Alkoxy, C 1-3 Haloalkoxy, or (C 1-3 Preferably, R1, R2, R3, R4, R5 are each independently selected from the group consisting of: H, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, fluoromethyl, chloromethyl, difluoromethyl, dichloromethyl, trifluoromethyl, trichloromethyl, 2,2-difluoroethyl, 2,2-dichloroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, pentachloroethyl, cyclopropyl, cyclo butyl, cyclopentyl, cyclohexyl, methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy, pentachloroethoxy, CH3C(=O)-, CH3CH2C(=O)-, FCH 2C(=O)-, ClCH2C(=O)-, F2CHC(=O)-, Cl2CHC(=O)-, CF3C(=O)-, CCl3C(=O)-, CF3CH2C( =O)-, CCl3CH2C(=O)-, (CH3)2N-, (CH3CH2)2N-, (CH3)2NC(=O)-, (CH3CH2)2NC(=O)-, cyano group The methyl, ethyl, n-propyl, isopropyl terminal carbon atom is optionally substituted by methoxy, ethoxy, n-propoxy, isopropoxy, fluoromethoxy, chloromethoxy, difluoromethoxy, dichloromethoxy, trifluoromethoxy, trichloromethoxy, 2,2-difluoroethoxy, 2,2-dichloroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, (CH3)2N-, or (CH3CH2)2N-.
6. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R6, R 7a , R 7b , R 7c , R 7d Each is independently selected from: H, F, Cl, Br, or I.
7. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, which is selected from:
8. The compound according to claim 2, its pharmaceutically acceptable salt or stereoisomer, which is selected from:
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.
10. Use of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof or a composition according to claim 9 in the preparation of a method for preventing and / or treating a MOR receptor agonist-mediated disease; preferably, the MOR receptor agonist-mediated disease includes pain, inflammation, immune dysfunction, esophageal reflux, neurological and psychiatric disorders, respiratory diseases, digestive system diseases, tumor system diseases, muscle and skeletal system diseases, ear, nose and throat diseases, skin diseases, blood and lymphatic system diseases, endocrine system diseases, vascular diseases, urinary and reproductive disorders, drug and alcohol abuse, gastritis or diarrhea, pruritus, anesthesia, sedation, infection; more preferably, the pain includes neuropathic pain, traumatic pain, nociceptive pain, mixed pain, postoperative pain, inflammatory pain, visceral pain, migraine and cancer-related pain.
Citation Information
Patent Citations
2,6-Dioxaspiro[4,5]decane derivatives, their preparation methods and their pharmaceutical applications
CN111148515B
